ID   PTEN_HUMAN              Reviewed;         403 AA.
AC   P60484; B2R904; F2YHV0; O00633; O02679; Q6ICT7;
DT   16-FEB-2004, integrated into UniProtKB/Swiss-Prot.
DT   16-FEB-2004, sequence version 1.
DT   18-JUN-2025, entry version 223.
DE   RecName: Full=Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN {ECO:0000305|PubMed:9256433, ECO:0000305|PubMed:9811831};
DE            EC=3.1.3.16 {ECO:0000269|PubMed:9256433};
DE            EC=3.1.3.48 {ECO:0000269|PubMed:9187108, ECO:0000269|PubMed:9256433};
DE            EC=3.1.3.67 {ECO:0000269|PubMed:16824732, ECO:0000269|PubMed:9811831};
DE   AltName: Full=Inositol polyphosphate 3-phosphatase {ECO:0000305|PubMed:11418101, ECO:0000305|PubMed:9593664};
DE            EC=3.1.3.- {ECO:0000305|PubMed:11418101, ECO:0000305|PubMed:9593664};
DE   AltName: Full=Mutated in multiple advanced cancers 1;
DE   AltName: Full=Phosphatase and tensin homolog;
GN   Name=PTEN; Synonyms=MMAC1, TEP1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY,
RP   SUBCELLULAR LOCATION, AND INDUCTION.
RC   TISSUE=Epithelium;
RX   PubMed=9187108;
RA   Li D.M., Sun H.;
RT   "TEP1, encoded by a candidate tumor suppressor locus, is a novel protein
RT   tyrosine phosphatase regulated by transforming growth factor beta.";
RL   Cancer Res. 57:2124-2129(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND VARIANTS
RP   GLIOMA SER-15; GLU-36; ARG-42; TRP-57 AND THR-319 DEL.
RX   PubMed=9090379; DOI=10.1038/ng0497-356;
RA   Steck P.A., Pershouse M.A., Jasser S.A., Lin H., Yung W.K.A., Ligon A.H.,
RA   Langford L.A., Baumgard M.L., Hattier T., Davis T., Frye C., Hu R.,
RA   Swedlund B., Teng D.H.-F., Tavtigian S.V.;
RT   "Identification of a candidate tumour suppressor gene, MMAC1, at chromosome
RT   10q23.3 that is mutated in multiple advanced cancers.";
RL   Nat. Genet. 15:356-363(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT GLIOBLASTOMA ARG-129, AND
RP   VARIANT PROSTATE CANCER LEU-134.
RX   PubMed=9072974; DOI=10.1126/science.275.5308.1943;
RA   Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J.,
RA   Miliaresis C., Rodgers L., McCombie R., Bigner S.H., Giovanella B.C.,
RA   Ittmann M., Tycko B., Hibshoosh H., Wigler M.H., Parsons R.;
RT   "PTEN, a putative protein tyrosine phosphatase gene mutated in human brain,
RT   breast, and prostate cancer.";
RL   Science 275:1943-1947(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=10817502; DOI=10.1054/bjoc.2000.1211;
RA   Hamilton J.A., Stewart L.M.D., Ajayi L., Gray I.C., Gray N.E.,
RA   Roberts K.G., Watson G.J., Kaisary A.V., Snary D.;
RT   "The expression profile for the tumour suppressor gene PTEN and associated
RT   polymorphic markers.";
RL   Br. J. Cancer 82:1671-1676(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Wang S., Li J., Liaw D., Bose S., Podsypanina K., Parsons R.;
RL   Submitted (APR-1997) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Jensen K., de la Bastide M., Parsons R., Parnell L.D., Dedhia N.,
RA   Gottesman T., Gnoj L., Kaplan N., Lodhi M., Johnson A.F., Shohdy N.,
RA   Hasegawa A., Haberman K., Huang E.N., Schutz K., Calma C., Granat S.,
RA   Wigler M.H., McCombie W.R.;
RT   "Genomic sequence of PTEN/MMAC1.";
RL   Submitted (MAY-1998) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RA   Yang C.-W., Hsu Y.-F.;
RT   "Homo sapiens phosphatase and tensin homolog mRNA splicing variants.";
RL   Submitted (JAN-2011) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (MAY-2004) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LEU-290.
RG   NIEHS SNPs program;
RL   Submitted (MAY-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [13]
RP   FUNCTION, CATALYTIC ACTIVITY, AND CHARACTERIZATION OF VARIANTS GLIOMA
RP   TRP-57; ENDOMETRIAL CANCER TYR-123; GLIOBLASTOMA ARG-129; CWS1 ARG-129;
RP   PROSTATE CANCER LEU-134; GLIOBLASTOMA ARG-165; BREAST CANCER PRO-167 AND BZ
RP   ARG-170.
RX   PubMed=9256433; DOI=10.1073/pnas.94.17.9052;
RA   Myers M.P., Stolarov J.P., Eng C., Li J., Wang S.I., Wigler M.H.,
RA   Parsons R., Tonks N.K.;
RT   "P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-
RT   specificity phosphatase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:9052-9057(1997).
RN   [14]
RP   FUNCTION, CATALYTIC ACTIVITY, AND CHARACTERIZATION OF VARIANT CWS1 SER-124.
RX   PubMed=9593664; DOI=10.1074/jbc.273.22.13375;
RA   Maehama T., Dixon J.E.;
RT   "The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second
RT   messenger, phosphatidylinositol 3,4,5-trisphosphate.";
RL   J. Biol. Chem. 273:13375-13378(1998).
RN   [15]
RP   FUNCTION, CATALYTIC ACTIVITY, MUTAGENESIS OF ARG-130, AND CHARACTERIZATION
RP   OF VARIANTS CWS1 SER-124 AND CWS1 GLU-129.
RX   PubMed=9811831; DOI=10.1073/pnas.95.23.13513;
RA   Myers M.P., Pass I., Batty I.H., Van der Kaay J., Stolarov J.P.,
RA   Hemmings B.A., Wigler M.H., Downes C.P., Tonks N.K.;
RT   "The lipid phosphatase activity of PTEN is critical for its tumor
RT   suppressor function.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:13513-13518(1998).
RN   [16]
RP   FUNCTION, MUTAGENESIS OF ASP-92 AND CYS-124, AND CHARACTERIZATION OF
RP   VARIANT GLU-129.
RX   PubMed=9616126; DOI=10.1126/science.280.5369.1614;
RA   Tamura M., Gu J., Matsumoto K., Aota S., Parsons R., Yamada K.M.;
RT   "Inhibition of cell migration, spreading, and focal adhesions by tumor
RT   suppressor PTEN.";
RL   Science 280:1614-1617(1998).
RN   [17]
RP   FUNCTION, DOMAIN, AND CHARACTERIZATION OF VARIANTS THR-319 DEL; GLN-345 AND
RP   ILE-348.
RX   PubMed=10468583; DOI=10.1073/pnas.96.18.10182;
RA   Georgescu M.-M., Kirsch K.H., Akagi T., Shishido T., Hanafusa H.;
RT   "The tumor-suppressor activity of PTEN is regulated by its carboxyl-
RT   terminal region.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:10182-10187(1999).
RN   [18]
RP   INTERACTION WITH DLG1 AND MAST2, AND PHOSPHORYLATION AT THR-401.
RX   PubMed=10646847;
RA   Adey N.B., Huang L., Ormonde P.A., Baumgard M.L., Pero R., Byreddy D.V.,
RA   Tavtigian S.V., Bartel P.L.;
RT   "Threonine phosphorylation of the MMAC1/PTEN PDZ binding domain both
RT   inhibits and stimulates PDZ binding.";
RL   Cancer Res. 60:35-37(2000).
RN   [19]
RP   INTERACTION WITH MAGI3.
RX   PubMed=10748157; DOI=10.1074/jbc.m909741199;
RA   Wu Y., Dowbenko D., Spencer S., Laura R., Lee J., Gu Q., Lasky L.A.;
RT   "Interaction of the tumor suppressor PTEN/MMAC with a PDZ domain of MAGI3,
RT   a novel membrane-associated guanylate kinase.";
RL   J. Biol. Chem. 275:21477-21485(2000).
RN   [20]
RP   INTERACTION WITH MAGI2.
RX   PubMed=10760291; DOI=10.1073/pnas.97.8.4233;
RA   Wu X., Hepner K., Castelino-Prabhu S., Do D., Kaye M.B., Yuan X.-J.,
RA   Wood J., Ross C., Sawyers C.L., Whang Y.E.;
RT   "Evidence for regulation of the PTEN tumor suppressor by a membrane-
RT   localized multi-PDZ domain containing scaffold protein MAGI-2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:4233-4238(2000).
RN   [21]
RP   FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=11418101; DOI=10.1016/s0014-5793(01)02500-5;
RA   Caffrey J.J., Darden T., Wenk M.R., Shears S.B.;
RT   "Expanding coincident signaling by PTEN through its inositol 1,3,4,5,6-
RT   pentakisphosphate 3-phosphatase activity.";
RL   FEBS Lett. 499:6-10(2001).
RN   [22]
RP   PHOSPHORYLATION AT SER-370; SER-380; THR-382; THR-383 AND SER-385.
RX   PubMed=11035045; DOI=10.1074/jbc.m009134200;
RA   Torres J., Pulido R.;
RT   "The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at
RT   its C terminus. Implications for PTEN stability to proteasome-mediated
RT   degradation.";
RL   J. Biol. Chem. 276:993-998(2001).
RN   [23]
RP   FUNCTION, PHOSPHORYLATION, AND INTERACTION WITH MAGI2.
RX   PubMed=11707428; DOI=10.1074/jbc.c100556200;
RA   Vazquez F., Grossman S.R., Takahashi Y., Rokas M.V., Nakamura N.,
RA   Sellers W.R.;
RT   "Phosphorylation of the PTEN tail acts as an inhibitory switch by
RT   preventing its recruitment into a protein complex.";
RL   J. Biol. Chem. 276:48627-48630(2001).
RN   [24]
RP   PHOSPHORYLATION AT THR-366; SER-370 AND SER-385.
RX   PubMed=12297295; DOI=10.1016/s0014-5793(02)03274-x;
RA   Miller S., Lou D., Seldin D., Lane W., Neel B.;
RT   "Direct identification of PTEN phosphorylation sites.";
RL   FEBS Lett. 528:145-153(2002).
RN   [25]
RP   INTERACTION WITH NOP53, REGION, AND CHARACTERIZATION OF VARIANTS CWS1
RP   VAL-341; GLU-343 AND GLN-345.
RX   PubMed=15355975; DOI=10.1074/jbc.c400377200;
RA   Okahara F., Ikawa H., Kanaho Y., Maehama T.;
RT   "Regulation of PTEN phosphorylation and stability by a tumor suppressor
RT   candidate protein.";
RL   J. Biol. Chem. 279:45300-45303(2004).
RN   [26]
RP   INTERACTION WITH STK11, SUBCELLULAR LOCATION, AND PHOSPHORYLATION BY STK11.
RX   PubMed=15987703; DOI=10.1093/hmg/ddi225;
RA   Mehenni H., Lin-Marq N., Buchet-Poyau K., Reymond A., Collart M.A.,
RA   Picard D., Antonarakis S.E.;
RT   "LKB1 interacts with and phosphorylates PTEN: a functional link between two
RT   proteins involved in cancer predisposing syndromes.";
RL   Hum. Mol. Genet. 14:2209-2219(2005).
RN   [27]
RP   INTERACTION WITH MAGI2; MAGI3; MAST1; MAST2 AND MAST3, MUTAGENESIS OF
RP   VAL-403, AND PHOSPHORYLATION.
RX   PubMed=15951562; DOI=10.1074/jbc.m504761200;
RA   Valiente M., Andres-Pons A., Gomar B., Torres J., Gil A., Tapparel C.,
RA   Antonarakis S.E., Pulido R.;
RT   "Binding of PTEN to specific PDZ domains contributes to PTEN protein
RT   stability and phosphorylation by microtubule-associated serine/threonine
RT   kinases.";
RL   J. Biol. Chem. 280:28936-28943(2005).
RN   [28]
RP   FUNCTION.
RX   PubMed=15979280; DOI=10.1016/j.cellsig.2005.05.017;
RA   Deleu S., Choi K., Pesesse X., Cho J., Sulis M.L., Parsons R., Shears S.B.;
RT   "Physiological levels of PTEN control the size of the cellular
RT   Ins(1,3,4,5,6)P(5) pool.";
RL   Cell. Signal. 18:488-498(2006).
RN   [29]
RP   CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND FUNCTION.
RX   PubMed=16824732; DOI=10.1016/j.cellsig.2006.05.010;
RA   Vandeput F., Backers K., Villeret V., Pesesse X., Erneux C.;
RT   "The influence of anionic lipids on SHIP2 phosphatidylinositol 3,4,5-
RT   trisphosphate 5-phosphatase activity.";
RL   Cell. Signal. 18:2193-2199(2006).
RN   [30]
RP   INTERACTION WITH NEDD4.
RX   PubMed=17218260; DOI=10.1016/j.cell.2006.11.039;
RA   Wang X., Trotman L.C., Koppie T., Alimonti A., Chen Z., Gao Z., Wang J.,
RA   Erdjument-Bromage H., Tempst P., Cordon-Cardo C., Pandolfi P.P., Jiang X.;
RT   "NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN.";
RL   Cell 128:129-139(2007).
RN   [31]
RP   FUNCTION, INTERACTION WITH USP7, UBIQUITINATION AT LYS-13 AND LYS-289,
RP   DEUBIQUITINATION BY USP7, SUBCELLULAR LOCATION, MUTAGENESIS OF LYS-13 AND
RP   LYS-289, AND CHARACTERIZATION OF VARIANT CWS1 GLU-289.
RX   PubMed=18716620; DOI=10.1038/nature07290;
RA   Song M.S., Salmena L., Carracedo A., Egia A., Lo-Coco F.,
RA   Teruya-Feldstein J., Pandolfi P.P.;
RT   "The deubiquitinylation and localization of PTEN are regulated by a HAUSP-
RT   PML network.";
RL   Nature 455:813-817(2008).
RN   [32]
RP   INTERACTION WITH FRK, PHOSPHORYLATION AT TYR-336, AND MUTAGENESIS OF
RP   TYR-336.
RX   PubMed=19345329; DOI=10.1016/j.ccr.2009.02.012;
RA   Yim E.-K., Peng G., Dai H., Hu R., Li K., Lu Y., Mills G.B.,
RA   Meric-Bernstam F., Hennessy B.T., Craven R.J., Lin S.-Y.;
RT   "Rak functions as a tumor suppressor by regulating PTEN protein stability
RT   and function.";
RL   Cancer Cell 15:304-314(2009).
RN   [33]
RP   UBIQUITINATION BY XIAP/BIRC4, SUBCELLULAR LOCATION, AND INTERACTION WITH
RP   XIAP/BIRC4.
RX   PubMed=19473982; DOI=10.1074/jbc.c109.009522;
RA   Van Themsche C., Leblanc V., Parent S., Asselin E.;
RT   "X-linked inhibitor of apoptosis protein (XIAP) regulates PTEN
RT   ubiquitination, content, and compartmentalization.";
RL   J. Biol. Chem. 284:20462-20466(2009).
RN   [34]
RP   PHOSPHORYLATION AT THR-366 AND SER-370, AND MUTAGENESIS OF THR-366 AND
RP   SER-370.
RX   PubMed=20940307; DOI=10.1074/jbc.m110.166462;
RA   Xu D., Yao Y., Jiang X., Lu L., Dai W.;
RT   "Regulation of PTEN stability and activity by Plk3.";
RL   J. Biol. Chem. 285:39935-39942(2010).
RN   [35]
RP   INTERACTION WITH NDFIP1 AND NDFIP2.
RX   PubMed=20534535; DOI=10.1073/pnas.0911714107;
RA   Mund T., Pelham H.R.;
RT   "Regulation of PTEN/Akt and MAP kinase signaling pathways by the ubiquitin
RT   ligase activators Ndfip1 and Ndfip2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:11429-11434(2010).
RN   [36]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [37]
RP   FUNCTION IN CELL MIGRATION.
RX   PubMed=22279049; DOI=10.1101/gad.177642.111;
RA   Stohr N., Kohn M., Lederer M., Glass M., Reinke C., Singer R.H.,
RA   Huttelmaier S.;
RT   "IGF2BP1 promotes cell migration by regulating MK5 and PTEN signaling.";
RL   Genes Dev. 26:176-189(2012).
RN   [38]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT THR-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [39]
RP   ALTERNATIVE INITIATION (ISOFORM ALPHA), CTG START CODON, FUNCTION (ISOFORM
RP   ALPHA), AND SUBCELLULAR LOCATION (ISOFORM ALPHA).
RX   PubMed=23744781; DOI=10.1126/science.1234907;
RA   Hopkins B.D., Fine B., Steinbach N., Dendy M., Rapp Z., Shaw J., Pappas K.,
RA   Yu J.S., Hodakoski C., Mense S., Klein J., Pegno S., Sulis M.L.,
RA   Goldstein H., Amendolara B., Lei L., Maurer M., Bruce J., Canoll P.,
RA   Hibshoosh H., Parsons R.;
RT   "A secreted PTEN phosphatase that enters cells to alter signaling and
RT   survival.";
RL   Science 341:399-402(2013).
RN   [40]
RP   INTERACTION WITH PPP1R16B.
RX   PubMed=25007873; DOI=10.1152/ajprenal.00070.2014;
RA   Obeidat M., Li L., Ballermann B.J.;
RT   "TIMAP promotes angiogenesis by suppressing PTEN-mediated Akt inhibition in
RT   human glomerular endothelial cells.";
RL   Am. J. Physiol. 307:F623-F633(2014).
RN   [41]
RP   ALTERNATIVE INITIATION (ISOFORM ALPHA), CTG START CODON, SUBCELLULAR
RP   LOCATION (ISOFORM ALPHA), AND MUTAGENESIS OF MET-1.
RX   PubMed=24768297; DOI=10.1016/j.cmet.2014.03.023;
RA   Liang H., He S., Yang J., Jia X., Wang P., Chen X., Zhang Z., Zou X.,
RA   McNutt M.A., Shen W.H., Yin Y.;
RT   "PTENalpha, a PTEN isoform translated through alternative initiation,
RT   regulates mitochondrial function and energy metabolism.";
RL   Cell Metab. 19:836-848(2014).
RN   [42]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-366, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [43]
RP   INTERACTION WITH NDFIP1, AND SUBCELLULAR LOCATION.
RX   PubMed=25801959; DOI=10.1093/jmcb/mjv020;
RA   Howitt J., Low L.H., Putz U., Doan A., Lackovic J., Goh C.P., Gunnersen J.,
RA   Silke J., Tan S.S.;
RT   "Ndfip1 represses cell proliferation by controlling Pten localization and
RT   signaling specificity.";
RL   J. Mol. Cell Biol. 7:119-131(2015).
RN   [44]
RP   FUNCTION, INTERACTION WITH TNS3 AND PI3K, PHOSPHORYLATION AT THR-319 AND
RP   THR-321, AND MUTAGENESIS OF SER-229; THR-232; THR-319 AND THR-321.
RX   PubMed=26166433; DOI=10.1038/ncomms8721;
RA   Cao X., Kaneko T., Li J.S., Liu A.D., Voss C., Li S.S.;
RT   "A phosphorylation switch controls the spatiotemporal activation of Rho
RT   GTPases in directional cell migration.";
RL   Nat. Commun. 6:7721-7721(2015).
RN   [45]
RP   FUNCTION, AND UBIQUITINATION.
RX   PubMed=31492966; DOI=10.1007/s00018-019-03280-5;
RA   Zhang J., Zhang Y.L., Zhao L.W., Pi S.B., Zhang S.Y., Tong C., Fan H.Y.;
RT   "The CRL4-DCAF13 ubiquitin E3 ligase supports oocyte meiotic resumption by
RT   targeting PTEN degradation.";
RL   Cell. Mol. Life Sci. 77:2181-2197(2020).
RN   [46]
RP   FUNCTION, AND ISGYLATION.
RX   PubMed=37279284; DOI=10.1126/scisignal.abm1756;
RA   Du X., Sheng J., Chen Y., He S., Yang Y., Huang Y., Fu Y., Lie L., Han Z.,
RA   Zhu B., Liu H., Wen Q., Zhou X., Zhou C., Hu S., Ma L.;
RT   "The E3 ligase HERC5 promotes antimycobacterial responses in macrophages by
RT   ISGylating the phosphatase PTEN.";
RL   Sci. Signal. 16:eabm1756-eabm1756(2023).
RN   [47]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 8-353 IN COMPLEX WITH
RP   L(+)-TARTRATE, SUBUNIT, DOMAIN, MUTAGENESIS OF ASP-92; HIS-93; LYS-125;
RP   LYS-128; THR-167; GLN-171; 263-LYS--ALA-269 AND 327-LYS--ALA-335, AND
RP   CATALYTIC ACTIVITY.
RX   PubMed=10555148; DOI=10.1016/s0092-8674(00)81663-3;
RA   Lee J.-O., Yang H., Georgescu M.-M., Di Cristofano A., Maehama T., Shi Y.,
RA   Dixon J.E., Pandolfi P., Pavletich N.P.;
RT   "Crystal structure of the PTEN tumor suppressor: implications for its
RT   phosphoinositide phosphatase activity and membrane association.";
RL   Cell 99:323-334(1999).
RN   [48]
RP   VARIANT CWS1 ASN-137 INS.
RX   PubMed=9345101; DOI=10.1086/301607;
RA   Tsou H.C., Teng D.H.-F., Ping X.L., Brancolini V., Davis T., Hu R.,
RA   Xie X.X., Gruener A.C., Schrager C.A., Christiano A.M., Eng C., Steck P.,
RA   Ott J., Tavtigian S.V., Peacocke M.;
RT   "The role of MMAC1 mutations in early-onset breast cancer: causative in
RT   association with Cowden syndrome and excluded in BRCA1-negative cases.";
RL   Am. J. Hum. Genet. 61:1036-1043(1997).
RN   [49]
RP   VARIANTS CWS1 GLU-343 AND LEU-347.
RX   PubMed=9399897; DOI=10.1086/301639;
RA   Lynch E.D., Ostermeyer E.A., Lee M.K., Arena J.F., Ji H., Dann J.,
RA   Swisshelm K., Suchard D., MacLeod P.M., Kvinnsland S., Gjertsen B.T.,
RA   Heimdal K., Lubs H., Moeller P., King M.-C.;
RT   "Inherited mutations in PTEN that are associated with breast cancer, Cowden
RT   disease, and juvenile polyposis.";
RL   Am. J. Hum. Genet. 61:1254-1260(1997).
RN   [50]
RP   VARIANTS GLIOBLASTOMA TYR-107; PRO-121; ARG-129; ARG-165 AND GLN-345.
RX   PubMed=9331071;
RA   Wang S.I., Puc J., Li J., Bruce J.N., Cairns P., Sidransky D., Parsons R.;
RT   "Somatic mutations of PTEN in glioblastoma multiforme.";
RL   Cancer Res. 57:4183-4186(1997).
RN   [51]
RP   VARIANTS CWS1 ARG-123 AND ARG-124.
RX   PubMed=9259288; DOI=10.1093/hmg/6.8.1383;
RA   Nelen M.R., van Staveren W.C.G., Peeters E.A.J., Ben-Hassel M.,
RA   Gorlin R.J., Hamm H., Lindboe C.F., Fryns J.-P., Sijmons R.H., Woods D.G.,
RA   Mariman E.C.M., Padberg G.W., Kremer H.;
RT   "Germline mutations in the PTEN/MMAC1 gene in patients with Cowden
RT   disease.";
RL   Hum. Mol. Genet. 6:1383-1387(1997).
RN   [52]
RP   VARIANT CWS1 GLU-129.
RX   PubMed=9140396; DOI=10.1038/ng0597-64;
RA   Liaw D., Marsh D.J., Li J., Dahia P.L.M., Wang S.I., Zheng Z., Bose S.,
RA   Call K.M., Tsou H.C., Peacocke M., Eng C., Parsons R.;
RT   "Germline mutations of the PTEN gene in Cowden disease, an inherited breast
RT   and thyroid cancer syndrome.";
RL   Nat. Genet. 16:64-67(1997).
RN   [53]
RP   VARIANT CWS1 ARG-170.
RX   PubMed=9241266; DOI=10.1038/ng0897-333;
RA   Marsh D.J., Dahia P.L.M., Zheng Z., Liaw D., Parsons R., Gorlin R.J.,
RA   Eng C.;
RT   "Germline mutations in PTEN are present in Bannayan-Zonana syndrome.";
RL   Nat. Genet. 16:333-334(1997).
RN   [54]
RP   VARIANTS ENDOMETRIAL HYPERPLASIA ARG-36; LEU-130; CYS-173; ALA-191 AND
RP   ILE-348.
RX   PubMed=9635567;
RA   Maxwell G.L., Risinger J.I., Gumbs C., Shaw H., Bentley R.C., Barrett J.C.,
RA   Berchuck A., Futreal P.A.;
RT   "Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias.";
RL   Cancer Res. 58:2500-2503(1998).
RN   [55]
RP   VARIANT CWS1 GLU-289.
RX   PubMed=9797362; DOI=10.1016/s0016-5085(98)70078-2;
RA   Chi S.-G., Kim H.-J., Park B.-J., Min H.-J., Park J.-H., Kim Y.-W.,
RA   Dong S.-H., Kim B.-H., Lee J.-I., Chang Y.-W., Chang R., Kim W.-K.,
RA   Yang M.-H.;
RT   "Mutational abrogation of the PTEN/MMAC1 gene in gastrointestinal polyps in
RT   patients with Cowden disease.";
RL   Gastroenterology 115:1084-1089(1998).
RN   [56]
RP   VARIANTS CWS1 HIS-68 AND PRO-112.
RX   PubMed=9600246; DOI=10.1007/s004390050723;
RA   Tsou H.C., Ping X.L., Xie X.X., Gruener A.C., Zhang H., Nini R.,
RA   Swisshelm K., Sybert V., Diamond T.M., Sutphen R., Peacocke M.;
RT   "The genetic basis of Cowden's syndrome: three novel mutations in
RT   PTEN/MMAC1/TEP1.";
RL   Hum. Genet. 102:467-473(1998).
RN   [57]
RP   VARIANTS CWS1 ARG-67 AND VAL-165.
RX   PubMed=9467011; DOI=10.1093/hmg/7.3.507;
RA   Marsh D.J., Coulon V., Lunetta K.L., Rocca-Serra P., Dahia P.L.M.,
RA   Zheng Z., Liaw D., Caron S., Duboue B., Lin A.Y., Richardson A.-L.,
RA   Bonnetblanc J.-M., Bressieux J.-M., Cabarrot-Moreau A., Chompret A.,
RA   Demange L., Eeles R.A., Yahanda A.M., Fearon E.R., Fricker J.-P.,
RA   Gorlin R.J., Hodgson S.V., Huson S., Lacombe D., Leprat F., Odent S.,
RA   Toulouse C., Olopade O.I., Sobol H., Tishler S., Woods C.G., Robinson B.G.,
RA   Weber H.C., Parsons R., Peacocke M., Longy M., Eng C.;
RT   "Mutation spectrum and genotype-phenotype analyses in Cowden disease and
RT   Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN
RT   mutation.";
RL   Hum. Mol. Genet. 7:507-515(1998).
RN   [58]
RP   VARIANT CWS1 TYR-136.
RX   PubMed=9735393; DOI=10.3892/ijo.13.4.665;
RA   Scala S., Bruni P., Lo Muzio L., Mignogna M., Viglietto G., Fusco A.;
RT   "Novel mutation of the PTEN gene in an Italian Cowden's disease kindred.";
RL   Int. J. Oncol. 13:665-668(1998).
RN   [59]
RP   VARIANT CWS1 PRO-70.
RX   PubMed=9832031; DOI=10.1136/jmg.35.11.881;
RA   Marsh D.J., Dahia P.L.M., Caron S., Kum J.B., Frayling I.M.,
RA   Tomlinson I.P.M., Hughes K.S., Eeles R.A., Hodgson S.V., Murday V.A.,
RA   Houlston R., Eng C.;
RT   "Germline PTEN mutations in Cowden syndrome-like families.";
RL   J. Med. Genet. 35:881-885(1998).
RN   [60]
RP   VARIANT CWS1 ARG-35.
RX   PubMed=9425889; DOI=10.1038/ng0198-12;
RA   Olschwang S., Serova-Sinilnikova O.M., Lenoir G.M., Thomas G.;
RT   "PTEN germ-line mutations in juvenile polyposis coli.";
RL   Nat. Genet. 18:12-14(1998).
RN   [61]
RP   VARIANT CWS1 GLN-130.
RX   PubMed=9915974; DOI=10.1086/302207;
RA   Kurose K., Araki T., Matsunaka T., Takada Y., Emi M.;
RT   "Variant manifestation of Cowden disease in Japan: hamartomatous polyposis
RT   of the digestive tract with mutation of the PTEN gene.";
RL   Am. J. Hum. Genet. 64:308-310(1999).
RN   [62]
RP   VARIANT CWS1/LDD PRO-112.
RX   PubMed=10051160;
RX   DOI=10.1002/(sici)1096-8628(19990212)82:4<290::aid-ajmg3>3.0.co;2-0;
RA   Sutphen R., Diamond T.M., Minton S.E., Peacocke M., Tsou H.C., Root A.W.;
RT   "Severe Lhermitte-Duclos disease with unique germline mutation of PTEN.";
RL   Am. J. Med. Genet. 82:290-293(1999).
RN   [63]
RP   VARIANTS CWS1 ILE-33 DEL; ARG-123; ARG-124 AND GLU-165.
RX   PubMed=10234502; DOI=10.1038/sj.ejhg.5200289;
RA   Nelen M.R., Kremer H., Konings I.B.M., Schoute F., van Essen A.J., Koch R.,
RA   Woods C.G., Fryns J.-P., Hamel B.C.J., Hoefsloot L.H., Peeters E.A.J.,
RA   Padberg G.W.;
RT   "Novel PTEN mutations in patients with Cowden disease: absence of clear
RT   genotype-phenotype correlations.";
RL   Eur. J. Hum. Genet. 7:267-273(1999).
RN   [64]
RP   VARIANTS CWS1 ASP-34; HIS-68; TYR-105; VAL-135; ARG-170 AND LEU-246.
RX   PubMed=10400993; DOI=10.1093/hmg/8.8.1461;
RA   Marsh D.J., Kum J.B., Lunetta K.L., Bennett M.J., Gorlin R.J., Ahmed S.F.,
RA   Bodurtha J., Crowe C., Curtis M.A., Dasouki M., Dunn T., Feit H.,
RA   Geraghty M.T., Graham J.M. Jr., Hodgson S.V., Hunter A., Korf B.R.,
RA   Manchester D., Miesfeldt S., Murday V.A., Nathanson K.L., Parisi M.,
RA   Pober B., Romano C., Tolmie J.L., Trembath R., Winter R.M., Zackai E.H.,
RA   Zori R.T., Weng L.-P., Dahia P.L.M., Eng C.;
RT   "PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-
RT   Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome.";
RL   Hum. Mol. Genet. 8:1461-1472(1999).
RN   [65]
RP   CHARACTERIZATION OF VARIANTS ASN-10; CYS-16; GLU-20; SER-27; ARG-61;
RP   HIS-68; ARG-112; PRO-121; ARG-129; GLY-130; ILE-133; LEU-134; ARG-165;
RP   ASN-170; CYS-173; HIS-173; PRO-173; ASN-174; PHE-227; CYS-251; GLN-345;
RP   GLY-369 AND ILE-401, AND CHARACTERIZATION OF VARIANTS CWS1 TYR-71; TYR-93;
RP   PHE-105; TYR-107; PRO-112; ARG-124; GLU-129; LEU-130; GLN-130; TYR-136;
RP   CYS-155; ARG-170; GLU-289; GLY-331; VAL-341; ASN-342; GLU-343 AND LEU-347.
RX   PubMed=10866302;
RA   Han S.-Y., Kato H., Kato S., Suzuki T., Shibata H., Ishii S., Shiiba K.,
RA   Matsuno S., Kanamaru R., Ishioka C.;
RT   "Functional evaluation of PTEN missense mutations using in vitro
RT   phosphoinositide phosphatase assay.";
RL   Cancer Res. 60:3147-3151(2000).
RN   [66]
RP   VARIANT CWS1 ARG-36.
RX   PubMed=10772390; DOI=10.1034/j.1600-0625.2000.009002152.x;
RA   Celebi J.T., Ping X.L., Zhang H., Remington T., Sulica V.I., Tsou H.C.,
RA   Peacocke M.;
RT   "Germline PTEN mutations in three families with Cowden syndrome.";
RL   Exp. Dermatol. 9:152-156(2000).
RN   [67]
RP   VARIANTS MULTIPLE CANCERS LEU-119 AND LEU-158.
RX   PubMed=10807691; DOI=10.1136/jmg.37.5.336;
RA   De Vivo I., Gertig D.M., Nagase S., Hankinson S.E., O'Brien R.,
RA   Speizer F.E., Parsons R., Hunter D.J.;
RT   "Novel germline mutations in the PTEN tumour suppressor gene found in women
RT   with multiple cancers.";
RL   J. Med. Genet. 37:336-341(2000).
RN   [68]
RP   VARIANTS MALIGNANT MELANOMA ASN-19 AND ILE-217.
RX   PubMed=10978354; DOI=10.1136/jmg.37.9.653;
RA   Celebi J.T., Shendrik I., Silvers D.N., Peacocke M.;
RT   "Identification of PTEN mutations in metastatic melanoma specimens.";
RL   J. Med. Genet. 37:653-657(2000).
RN   [69]
RP   CHARACTERIZATION OF VARIANTS CWS1 SER-124 AND GLU-129.
RX   PubMed=11230179; DOI=10.1093/hmg/10.6.599;
RA   Weng L.-P., Brown J.L., Eng C.;
RT   "PTEN coordinates G1 arrest by down-regulating cyclin D1 via its protein
RT   phosphatase activity and up-regulating p27 via its lipid phosphatase
RT   activity in a breast cancer model.";
RL   Hum. Mol. Genet. 10:599-604(2001).
RN   [70]
RP   VARIANT ASP-61.
RX   PubMed=11748304; DOI=10.1136/jmg.38.12.820;
RA   Reardon W., Zhou X.-P., Eng C.;
RT   "A novel germline mutation of the PTEN gene in a patient with macrocephaly,
RT   ventricular dilatation, and features of VATER association.";
RL   J. Med. Genet. 38:820-823(2001).
RN   [71]
RP   VARIANTS CWS1 ASP-34; GLY-47; HIS-68; TYR-105; VAL-135 AND ARG-170.
RX   PubMed=11494117; DOI=10.1038/sj.neo.7900154;
RA   Marsh D.J., Theodosopoulos G., Howell V., Richardson A.-L., Benn D.E.,
RA   Proos A.L., Eng C., Robinson B.G.;
RT   "Rapid mutation scanning of genes associated with familial cancer syndromes
RT   using denaturing high-performance liquid chromatography.";
RL   Neoplasia 3:236-244(2001).
RN   [72]
RP   VARIANT GLM2 GLN-234, AND CHARACTERIZATION OF VARIANT GLM2 GLN-234.
RX   PubMed=12085208; DOI=10.1038/sj.bjc.6600206;
RA   Staal F.J.T., van der Luijt R.B., Baert M.R.M., van Drunen J.,
RA   van Bakel H., Peters E., de Valk I., van Amstel H.K.P., Taphoorn M.J.B.,
RA   Jansen G.H., van Veelen C.W.M., Burgering B., Staal G.E.J.;
RT   "A novel germline mutation of PTEN associated with brain tumours of
RT   multiple lineages.";
RL   Br. J. Cancer 86:1586-1591(2002).
RN   [73]
RP   VARIANT HNSCC GLY-121.
RX   PubMed=11801303; DOI=10.1016/s0165-4608(01)00509-x;
RA   Poetsch M., Lorenz G., Kleist B.;
RT   "Detection of new PTEN/MMAC1 mutations in head and neck squamous cell
RT   carcinomas with loss of chromosome 10.";
RL   Cancer Genet. Cytogenet. 132:20-24(2002).
RN   [74]
RP   DISCUSSION OF PTEN INVOLVEMENT IN PROTEUS SYNDROME.
RX   PubMed=12471211; DOI=10.1136/jmg.39.12.937;
RA   Smith J.M., Kirk E.P.E., Theodosopoulos G., Marshall G.M., Walker J.,
RA   Rogers M., Field M., Brereton J.J., Marsh D.J.;
RT   "Germline mutation of the tumour suppressor PTEN in Proteus syndrome.";
RL   J. Med. Genet. 39:937-940(2002).
RN   [75]
RP   VARIANTS MCEPHAS ARG-93; SER-241 AND GLY-252.
RX   PubMed=15805158; DOI=10.1136/jmg.2004.024646;
RA   Butler M.G., Dasouki M.J., Zhou X.-P., Talebizadeh Z., Brown M.,
RA   Takahashi T.N., Miles J.H., Wang C.H., Stratton R., Pilarski R., Eng C.;
RT   "Subset of individuals with autism spectrum disorders and extreme
RT   macrocephaly associated with germline PTEN tumour suppressor gene
RT   mutations.";
RL   J. Med. Genet. 42:318-321(2005).
RN   [76]
RP   VARIANT ENDMC GLU-36.
RX   PubMed=16506206; DOI=10.1002/ijc.21862;
RA   Bilbao C., Rodriguez G., Ramirez R., Falcon O., Leon L., Chirino R.,
RA   Rivero J.F., Falcon O. Jr., Diaz-Chico B.N., Diaz-Chico J.C., Perucho M.;
RT   "The relationship between microsatellite instability and PTEN gene
RT   mutations in endometrial cancer.";
RL   Int. J. Cancer 119:563-570(2006).
RN   [77]
RP   INVOLVEMENT IN CHROMOSOME 10Q23 DELETION SYNDROME.
RX   PubMed=17436248; DOI=10.1086/513607;
RA   Balciuniene J., Feng N., Iyadurai K., Hirsch B., Charnas L., Bill B.R.,
RA   Easterday M.C., Staaf J., Oseth L., Czapansky-Beilman D., Avramopoulos D.,
RA   Thomas G.H., Borg A., Valle D., Schimmenti L.A., Selleck S.B.;
RT   "Recurrent 10q22-q23 deletions: a genomic disorder on 10q associated with
RT   cognitive and behavioral abnormalities.";
RL   Am. J. Hum. Genet. 80:938-947(2007).
RN   [78]
RP   VARIANT VAL-132.
RX   PubMed=16752378; DOI=10.1002/ajmg.a.31273;
RA   Tekin M., Hismi B.O., Fitoz S., Yalcinkaya F., Ekim M., Kansu A., Ertem M.,
RA   Deda G., Tutar E., Arsan S., Zhou X.-P., Pilarski R., Eng C., Akar N.;
RT   "A germline PTEN mutation with manifestations of prenatal onset and
RT   verrucous epidermal nevus.";
RL   Am. J. Med. Genet. A 140:1472-1475(2006).
RN   [79]
RP   VARIANTS CWS1 SER-15; ASP-34; ARG-36; ARG-61; HIS-68; GLU-129; GLY-130;
RP   LEU-130; GLN-130; TYR-136; ARG-165; ARG-170; GLY-252 AND LEU-347.
RX   PubMed=21659347; DOI=10.1136/jmg.2011.088807;
RA   Pilarski R., Stephens J.A., Noss R., Fisher J.L., Prior T.W.;
RT   "Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan-
RT   Riley-Ruvalcaba syndrome clinical features.";
RL   J. Med. Genet. 48:505-512(2011).
RN   [80]
RP   VARIANTS MCEPHAS ILE-131 AND ASN-167.
RX   PubMed=23160955; DOI=10.1126/science.1227764;
RA   O'Roak B.J., Vives L., Fu W., Egertson J.D., Stanaway I.B., Phelps I.G.,
RA   Carvill G., Kumar A., Lee C., Ankenman K., Munson J., Hiatt J.B.,
RA   Turner E.H., Levy R., O'Day D.R., Krumm N., Coe B.P., Martin B.K.,
RA   Borenstein E., Nickerson D.A., Mefford H.C., Doherty D., Akey J.M.,
RA   Bernier R., Eichler E.E., Shendure J.;
RT   "Multiplex targeted sequencing identifies recurrently mutated genes in
RT   autism spectrum disorders.";
RL   Science 338:1619-1622(2012).
RN   [81]
RP   VARIANTS CWS1 ARG-61; TYR-93; GLY-130; GLN-130; LEU-130 AND CYS-173.
RX   PubMed=24778394; DOI=10.1200/jco.2013.53.6656;
RA   Ngeow J., Stanuch K., Mester J.L., Barnholtz-Sloan J.S., Eng C.;
RT   "Second malignant neoplasms in patients with Cowden syndrome with
RT   underlying germline PTEN mutations.";
RL   J. Clin. Oncol. 32:1818-1824(2014).
RN   [82]
RP   VARIANT MCEPHAS 65-TYR--VAL-403 DEL.
RX   PubMed=26637798; DOI=10.1016/j.neuron.2015.11.009;
RA   D'Gama A.M., Pochareddy S., Li M., Jamuar S.S., Reiff R.E., Lam A.T.,
RA   Sestan N., Walsh C.A.;
RT   "Targeted DNA Sequencing from Autism Spectrum Disorder Brains Implicates
RT   Multiple Genetic Mechanisms.";
RL   Neuron 88:910-917(2015).
RN   [83]
RP   VARIANT PROSTATE CANCER GLY-126, CHARACTERIZATION OF VARIANT GLY-126,
RP   MUTAGENESIS OF ALA-126, AND FUNCTION.
RX   PubMed=26504226; DOI=10.1073/pnas.1422504112;
RA   Costa H.A., Leitner M.G., Sos M.L., Mavrantoni A., Rychkova A.,
RA   Johnson J.R., Newton B.W., Yee M.C., De La Vega F.M., Ford J.M.,
RA   Krogan N.J., Shokat K.M., Oliver D., Halaszovich C.R., Bustamante C.D.;
RT   "Discovery and functional characterization of a neomorphic PTEN mutation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 112:13976-13981(2015).
RN   [84]
RP   VARIANT ASN-174.
RX   PubMed=39316756; DOI=10.1158/0008-5472.can-23-2216;
RA   Plitt G., Brewer T., Yehia L., Rabinowitz L., Griffith C.C., Eng C.;
RT   "The genomic landscape of benign and malignant thyroid tumors from
RT   individuals carrying germline PTEN variants is distinct from sporadic
RT   thyroid cancers.";
RL   Cancer Res. 84:3657-3668(2024).
CC   -!- FUNCTION: Dual-specificity protein phosphatase, dephosphorylating
CC       tyrosine-, serine- and threonine-phosphorylated proteins
CC       (PubMed:9187108, PubMed:9256433, PubMed:9616126). Also functions as a
CC       lipid phosphatase, removing the phosphate in the D3 position of the
CC       inositol ring of PtdIns(3,4,5)P3/phosphatidylinositol 3,4,5-
CC       trisphosphate, PtdIns(3,4)P2/phosphatidylinositol 3,4-diphosphate and
CC       PtdIns3P/phosphatidylinositol 3-phosphate with a preference for
CC       PtdIns(3,4,5)P3 (PubMed:16824732, PubMed:26504226, PubMed:9593664,
CC       PubMed:9811831). Furthermore, this enzyme can also act as a cytosolic
CC       inositol 3-phosphatase acting on Ins(1,3,4,5,6)P5/inositol 1,3,4,5,6
CC       pentakisphosphate and possibly Ins(1,3,4,5)P4/1D-myo-inositol 1,3,4,5-
CC       tetrakisphosphate (PubMed:11418101, PubMed:15979280). Antagonizes the
CC       PI3K-AKT/PKB signaling pathway by dephosphorylating phosphoinositides
CC       and thereby modulating cell cycle progression and cell survival
CC       (PubMed:31492966, PubMed:37279284). The unphosphorylated form
CC       cooperates with MAGI2 to suppress AKT1 activation (PubMed:11707428). In
CC       motile cells, suppresses the formation of lateral pseudopods and
CC       thereby promotes cell polarization and directed movement
CC       (PubMed:22279049). Dephosphorylates tyrosine-phosphorylated focal
CC       adhesion kinase and inhibits cell migration and integrin-mediated cell
CC       spreading and focal adhesion formation (PubMed:22279049). Required for
CC       growth factor-induced epithelial cell migration; growth factor
CC       stimulation induces PTEN phosphorylation which changes its binding
CC       preference from the p85 regulatory subunit of the PI3K kinase complex
CC       to DLC1 and results in translocation of the PTEN-DLC1 complex to the
CC       posterior of migrating cells to promote RHOA activation
CC       (PubMed:26166433). Meanwhile, TNS3 switches binding preference from
CC       DLC1 to p85 and the TNS3-p85 complex translocates to the leading edge
CC       of migrating cells to activate RAC1 activation (PubMed:26166433). Plays
CC       a role as a key modulator of the AKT-mTOR signaling pathway controlling
CC       the tempo of the process of newborn neurons integration during adult
CC       neurogenesis, including correct neuron positioning, dendritic
CC       development and synapse formation (By similarity). Involved in the
CC       regulation of synaptic function in excitatory hippocampal synapses.
CC       Recruited to the postsynaptic membrane upon NMDA receptor activation,
CC       is required for the modulation of synaptic activity during plasticity.
CC       Enhancement of lipid phosphatase activity is able to drive depression
CC       of AMPA receptor-mediated synaptic responses, activity required for
CC       NMDA receptor-dependent long-term depression (LTD) (By similarity). May
CC       be a negative regulator of insulin signaling and glucose metabolism in
CC       adipose tissue. The nuclear monoubiquitinated form possesses greater
CC       apoptotic potential, whereas the cytoplasmic nonubiquitinated form
CC       induces less tumor suppressive ability (PubMed:10468583,
CC       PubMed:18716620). {ECO:0000250|UniProtKB:O08586,
CC       ECO:0000250|UniProtKB:O54857, ECO:0000269|PubMed:10468583,
CC       ECO:0000269|PubMed:11418101, ECO:0000269|PubMed:11707428,
CC       ECO:0000269|PubMed:15979280, ECO:0000269|PubMed:16824732,
CC       ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:22279049,
CC       ECO:0000269|PubMed:26166433, ECO:0000269|PubMed:26504226,
CC       ECO:0000269|PubMed:31492966, ECO:0000269|PubMed:37279284,
CC       ECO:0000269|PubMed:9187108, ECO:0000269|PubMed:9256433,
CC       ECO:0000269|PubMed:9593664, ECO:0000269|PubMed:9616126,
CC       ECO:0000269|PubMed:9811831}.
CC   -!- FUNCTION: [Isoform alpha]: Functional kinase, like isoform 1 it
CC       antagonizes the PI3K-AKT/PKB signaling pathway. Plays a role in
CC       mitochondrial energetic metabolism by promoting COX activity and ATP
CC       production, via collaboration with isoform 1 in increasing protein
CC       levels of PINK1. {ECO:0000269|PubMed:23744781}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4,5-
CC         trisphosphate) + H2O = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-
CC         inositol-4,5-bisphosphate) + phosphate; Xref=Rhea:RHEA:25017,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:57836,
CC         ChEBI:CHEBI:58456; EC=3.1.3.67;
CC         Evidence={ECO:0000269|PubMed:16824732, ECO:0000269|PubMed:9811831};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:25018;
CC         Evidence={ECO:0000305|PubMed:16824732};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=O-phospho-L-seryl-[protein] + H2O = L-seryl-[protein] +
CC         phosphate; Xref=Rhea:RHEA:20629, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15377, ChEBI:CHEBI:29999, ChEBI:CHEBI:43474,
CC         ChEBI:CHEBI:83421; EC=3.1.3.16;
CC         Evidence={ECO:0000269|PubMed:9256433};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:20630;
CC         Evidence={ECO:0000305|PubMed:9256433};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=O-phospho-L-threonyl-[protein] + H2O = L-threonyl-[protein] +
CC         phosphate; Xref=Rhea:RHEA:47004, Rhea:RHEA-COMP:11060, Rhea:RHEA-
CC         COMP:11605, ChEBI:CHEBI:15377, ChEBI:CHEBI:30013, ChEBI:CHEBI:43474,
CC         ChEBI:CHEBI:61977; EC=3.1.3.16;
CC         Evidence={ECO:0000269|PubMed:9256433};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:47005;
CC         Evidence={ECO:0000305|PubMed:9256433};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=O-phospho-L-tyrosyl-[protein] + H2O = L-tyrosyl-[protein] +
CC         phosphate; Xref=Rhea:RHEA:10684, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:20101, ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:61978; EC=3.1.3.48; Evidence={ECO:0000269|PubMed:9187108,
CC         ECO:0000269|PubMed:9256433};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:10685;
CC         Evidence={ECO:0000305|PubMed:9256433};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4,5-
CC         trisphosphate) + H2O = 1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo-
CC         inositol-4,5-bisphosphate) + phosphate; Xref=Rhea:RHEA:43552,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:83416,
CC         ChEBI:CHEBI:83419; Evidence={ECO:0000269|PubMed:16824732,
CC         ECO:0000269|PubMed:9593664};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:43553;
CC         Evidence={ECO:0000305|PubMed:16824732};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1,2-dihexadecanoyl-sn-glycero-3-phospho-(1D-myo-
CC         inositol-3,4,5-trisphosphate) + H2O = 1,2-dihexadecanoyl-sn-glycero-
CC         3-phospho-(1D-myo-inositol-4,5-bisphosphate) + phosphate;
CC         Xref=Rhea:RHEA:43560, ChEBI:CHEBI:15377, ChEBI:CHEBI:43474,
CC         ChEBI:CHEBI:83420, ChEBI:CHEBI:83423;
CC         Evidence={ECO:0000269|PubMed:16824732, ECO:0000269|PubMed:9593664};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:43561;
CC         Evidence={ECO:0000305|PubMed:16824732};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1D-myo-inositol 1,3,4,5,6-pentakisphosphate + H2O = 1D-myo-
CC         inositol 1,4,5,6-tetrakisphosphate + phosphate; Xref=Rhea:RHEA:77143,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:57627,
CC         ChEBI:CHEBI:57733; Evidence={ECO:0000269|PubMed:11418101};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:77144;
CC         Evidence={ECO:0000269|PubMed:11418101};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1D-myo-inositol 1,3,4,5-tetrakisphosphate + H2O = 1D-myo-
CC         inositol 1,4,5-trisphosphate + phosphate; Xref=Rhea:RHEA:77155,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:57895,
CC         ChEBI:CHEBI:203600; Evidence={ECO:0000269|PubMed:9593664};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:77156;
CC         Evidence={ECO:0000305|PubMed:9593664};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- ACTIVITY REGULATION: Enzymatic activity is enhanced in the presence of
CC       phosphatidylserine. {ECO:0000269|PubMed:16824732}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=26 uM for PtdIns(3,4,5)P3 {ECO:0000269|PubMed:11418101};
CC         KM=11.5 uM for 1D-myo-inositol 1,3,4-trisphosphate
CC         {ECO:0000269|PubMed:11418101};
CC         KM=4.6 uM for 1D-myo-inositol 1,3,4,5-tetrakisphosphate
CC         {ECO:0000269|PubMed:11418101};
CC         KM=7.1 uM for 1D-myo-inositol 1,3,4,5,6-pentakisphosphate
CC         {ECO:0000269|PubMed:11418101};
CC         Vmax=60 nmol/min/mg enzyme with PtdIns(3,4,5)P3 as substrate
CC         {ECO:0000269|PubMed:11418101};
CC         Vmax=24 nmol/min/mg enzyme with 1D-myo-inositol 1,3,4-trisphosphate
CC         as substrate {ECO:0000269|PubMed:11418101};
CC         Vmax=112 nmol/min/mg enzyme with 1D-myo-inositol
CC         1,3,4,5-tetrakisphosphate as substrate {ECO:0000269|PubMed:11418101};
CC         Vmax=67 nmol/min/mg enzyme with 1D-myo-inositol
CC         1,3,4,5,6-pentakisphosphate as substrate
CC         {ECO:0000269|PubMed:11418101};
CC   -!- SUBUNIT: Monomer. The unphosphorylated form interacts with the second
CC       PDZ domain of MAGI2 and with DLG1 and MAST2 in vitro (PubMed:10646847,
CC       PubMed:10760291, PubMed:11707428). Interacts with MAGI2, MAGI3, MAST1
CC       and MAST3, but neither with MAST4 nor with DLG5; interaction with MAGI2
CC       increases protein stability (PubMed:10748157, PubMed:15951562).
CC       Interacts with NEDD4 (PubMed:17218260). Interacts with NDFIP1 and
CC       NDFIP2; in the presence of NEDD4 or ITCH, this interaction promotes
CC       PTEN ubiquitination (PubMed:20534535, PubMed:25801959). Interacts (via
CC       C2 domain) with FRK (PubMed:19345329). Interacts with USP7; the
CC       interaction is direct (PubMed:18716620). Interacts with ROCK1 (By
CC       similarity). Interacts with XIAP/BIRC4 (PubMed:19473982). Interacts
CC       with STK11; the interaction phosphorylates PTEN (PubMed:15987703).
CC       Interacts with PPP1R16B (PubMed:25007873). Interacts with NOP53;
CC       regulates PTEN phosphorylation and increases its stability
CC       (PubMed:15355975). Interacts (via PDZ domain-binding motif) with DLG4;
CC       the interaction is induced by NMDA and is required for PTEN location at
CC       postsynaptic density (By similarity). Interacts with the regulatory p85
CC       subunit of the PI3K kinase complex and with Rho GTPase-activating
CC       protein DLC1; in resting cells, interacts (via C2 tensin-type domain)
CC       with p85 but, following growth factor stimulation, PTEN is
CC       phosphorylated which leads to weakened interaction with p85 and
CC       enhanced interaction (via C2 tensin-type domain) with DLC1 while p85
CC       interaction with TNS3 increases (PubMed:26166433).
CC       {ECO:0000250|UniProtKB:O08586, ECO:0000250|UniProtKB:O54857,
CC       ECO:0000269|PubMed:10555148, ECO:0000269|PubMed:10646847,
CC       ECO:0000269|PubMed:10748157, ECO:0000269|PubMed:10760291,
CC       ECO:0000269|PubMed:11707428, ECO:0000269|PubMed:15355975,
CC       ECO:0000269|PubMed:15951562, ECO:0000269|PubMed:15987703,
CC       ECO:0000269|PubMed:17218260, ECO:0000269|PubMed:18716620,
CC       ECO:0000269|PubMed:19345329, ECO:0000269|PubMed:19473982,
CC       ECO:0000269|PubMed:20534535, ECO:0000269|PubMed:25007873,
CC       ECO:0000269|PubMed:25801959, ECO:0000269|PubMed:26166433}.
CC   -!- INTERACTION:
CC       P60484; Q9ULX6: AKAP8L; NbExp=2; IntAct=EBI-696162, EBI-357530;
CC       P60484; P35226: BMI1; NbExp=7; IntAct=EBI-696162, EBI-2341576;
CC       P60484; P30260: CDC27; NbExp=7; IntAct=EBI-696162, EBI-994813;
CC       P60484; Q9P0U4: CXXC1; NbExp=2; IntAct=EBI-696162, EBI-949911;
CC       P60484; Q16643: DBN1; NbExp=5; IntAct=EBI-696162, EBI-351394;
CC       P60484; P42685: FRK; NbExp=7; IntAct=EBI-696162, EBI-1383583;
CC       P60484; O60307: MAST3; NbExp=3; IntAct=EBI-696162, EBI-311420;
CC       P60484; Q9Y6Q9: NCOA3; NbExp=2; IntAct=EBI-696162, EBI-81196;
CC       P60484; P46934: NEDD4; NbExp=4; IntAct=EBI-696162, EBI-726944;
CC       P60484; O14745: NHERF1; NbExp=7; IntAct=EBI-696162, EBI-349787;
CC       P60484; Q15599: NHERF2; NbExp=5; IntAct=EBI-696162, EBI-1149760;
CC       P60484; P09619: PDGFRB; NbExp=3; IntAct=EBI-696162, EBI-641237;
CC       P60484; Q9NRD5: PICK1; NbExp=2; IntAct=EBI-696162, EBI-79165;
CC       P60484; P62136: PPP1CA; NbExp=2; IntAct=EBI-696162, EBI-357253;
CC       P60484; Q06830: PRDX1; NbExp=7; IntAct=EBI-696162, EBI-353193;
CC       P60484; P60484: PTEN; NbExp=9; IntAct=EBI-696162, EBI-696162;
CC       P60484; O43791: SPOP; NbExp=4; IntAct=EBI-696162, EBI-743549;
CC       P60484; Q62696: Dlg1; Xeno; NbExp=2; IntAct=EBI-696162, EBI-389325;
CC       P60484; O88382: Magi2; Xeno; NbExp=3; IntAct=EBI-696162, EBI-696179;
CC       P60484; Q9JK71: Magi3; Xeno; NbExp=3; IntAct=EBI-696162, EBI-696226;
CC       P60484; Q9R1L5: Mast1; Xeno; NbExp=3; IntAct=EBI-696162, EBI-491771;
CC       P60484; Q60592: Mast2; Xeno; NbExp=4; IntAct=EBI-696162, EBI-493888;
CC       P60484; Q9JHL1: Nherf2; Xeno; NbExp=2; IntAct=EBI-696162, EBI-538451;
CC       P60484-1; Q19T08: ECSCR; NbExp=4; IntAct=EBI-15722967, EBI-15778214;
CC       P60484-1; Q5T2D3: OTUD3; NbExp=9; IntAct=EBI-15722967, EBI-16170539;
CC       P60484-1; P60484-1: PTEN; NbExp=3; IntAct=EBI-15722967, EBI-15722967;
CC       P60484-1; Q93009: USP7; NbExp=5; IntAct=EBI-15722967, EBI-302474;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15987703,
CC       ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:19473982,
CC       ECO:0000269|PubMed:25801959, ECO:0000269|PubMed:9187108}. Nucleus
CC       {ECO:0000269|PubMed:15987703, ECO:0000269|PubMed:18716620,
CC       ECO:0000269|PubMed:19473982, ECO:0000269|PubMed:25801959}. Nucleus, PML
CC       body {ECO:0000269|PubMed:18716620}. Cell projection, dendritic spine
CC       {ECO:0000250|UniProtKB:O54857}. Postsynaptic density
CC       {ECO:0000250|UniProtKB:O54857}. Note=Monoubiquitinated form is nuclear.
CC       Nonubiquitinated form is cytoplasmic. Colocalized with PML and USP7 in
CC       PML nuclear bodies (PubMed:18716620). XIAP/BIRC4 promotes its nuclear
CC       localization (PubMed:19473982). Associares with the postsynaptic
CC       density in response to NMDAR activation (By similarity).
CC       {ECO:0000250|UniProtKB:O54857, ECO:0000269|PubMed:18716620,
CC       ECO:0000269|PubMed:19473982}.
CC   -!- SUBCELLULAR LOCATION: [Isoform alpha]: Secreted
CC       {ECO:0000269|PubMed:23744781, ECO:0000269|PubMed:24768297}. Note=May be
CC       secreted via a classical signal peptide and reenter into cells with the
CC       help of a poly-Arg motif. {ECO:0000269|PubMed:23744781,
CC       ECO:0000269|PubMed:24768297}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing, Alternative initiation; Named isoforms=3;
CC       Name=1; Synonyms=55kDa;
CC         IsoId=P60484-1; Sequence=Displayed;
CC       Name=alpha; Synonyms=70kDa, PTEN-long;
CC         IsoId=P60484-2; Sequence=VSP_055420;
CC       Name=3;
CC         IsoId=P60484-3; Sequence=VSP_055421, VSP_055422, VSP_055423;
CC   -!- TISSUE SPECIFICITY: Expressed at a relatively high level in all adult
CC       tissues, including heart, brain, placenta, lung, liver, muscle, kidney
CC       and pancreas. {ECO:0000269|PubMed:9090379}.
CC   -!- INDUCTION: Down-regulated by TGFB1. {ECO:0000269|PubMed:9187108}.
CC   -!- DOMAIN: The C2 domain binds phospholipid membranes in vitro in a
CC       Ca(2+)-independent manner; this binding is important for its tumor
CC       suppressor function. {ECO:0000269|PubMed:10468583,
CC       ECO:0000269|PubMed:10555148}.
CC   -!- PTM: Constitutively phosphorylated by CK2 under normal conditions.
CC       Phosphorylated in vitro by MAST1, MAST2, MAST3 and STK11.
CC       Phosphorylation results in an inhibited activity towards PIP3.
CC       Phosphorylation can both inhibit or promote PDZ-binding.
CC       Phosphorylation at Tyr-336 by FRK/PTK5 protects this protein from
CC       ubiquitin-mediated degradation probably by inhibiting its binding to
CC       NEDD4. Phosphorylation by ROCK1 is essential for its stability and
CC       activity. Phosphorylation by PLK3 promotes its stability and prevents
CC       its degradation by the proteasome. Phosphorylated on Thr-319 and Thr-
CC       321 in the C2-type tensin domain following EGF stimulation which
CC       changes its binding preference from the p85 regulatory subunit of the
CC       PI3K kinase complex to DLC1 (PubMed:26166433).
CC       {ECO:0000269|PubMed:10646847, ECO:0000269|PubMed:11035045,
CC       ECO:0000269|PubMed:11707428, ECO:0000269|PubMed:12297295,
CC       ECO:0000269|PubMed:15951562, ECO:0000269|PubMed:15987703,
CC       ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:19345329,
CC       ECO:0000269|PubMed:20940307, ECO:0000269|PubMed:26166433}.
CC   -!- PTM: Monoubiquitinated; monoubiquitination is increased in presence of
CC       retinoic acid. Deubiquitinated by USP7; leading to its nuclear
CC       exclusion. Monoubiquitination of one of either Lys-13 and Lys-289 amino
CC       acid is sufficient to modulate PTEN compartmentalization. Ubiquitinated
CC       by XIAP/BIRC4. {ECO:0000269|PubMed:18716620,
CC       ECO:0000269|PubMed:19473982}.
CC   -!- PTM: Ubiquitinated by the DCX(DCAF13) E3 ubiquitin ligase complex,
CC       leading to its degradation. {ECO:0000269|PubMed:31492966}.
CC   -!- PTM: ISGylated. ISGylation promotes PTEN degradation.
CC       {ECO:0000269|PubMed:37279284}.
CC   -!- DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant
CC       hamartomatous polyposis syndrome with age-related penetrance. Cowden
CC       syndrome is characterized by hamartomatous lesions affecting
CC       derivatives of ectodermal, mesodermal and endodermal layers,
CC       macrocephaly, facial trichilemmomas (benign tumors of the hair follicle
CC       infundibulum), acral keratoses, papillomatous papules, and elevated
CC       risk for development of several types of malignancy, particularly
CC       breast carcinoma in women and thyroid carcinoma in both men and women.
CC       Colon cancer and renal cell carcinoma have also been reported.
CC       Hamartomas can be found in virtually every organ, but most commonly in
CC       the skin, gastrointestinal tract, breast and thyroid.
CC       {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502,
CC       ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:10772390,
CC       ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:11230179,
CC       ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:15355975,
CC       ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:21659347,
CC       ECO:0000269|PubMed:24778394, ECO:0000269|PubMed:9140396,
CC       ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9259288,
CC       ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897,
CC       ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9467011,
CC       ECO:0000269|PubMed:9593664, ECO:0000269|PubMed:9600246,
CC       ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362,
CC       ECO:0000269|PubMed:9811831, ECO:0000269|PubMed:9832031,
CC       ECO:0000269|PubMed:9915974}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease
CC       characterized by the occurrence of a slowly enlarging mass within the
CC       cerebellar cortex corresponding histologically to a cerebellar
CC       hamartoma. It manifests, most commonly in the third and fourth decades
CC       of life, with increased intracranial pressure, headache, nausea,
CC       cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual
CC       disturbances and other cranial nerve palsies. Various associated
CC       abnormalities may be present such as megalencephaly, microgyria,
CC       hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part
CC       of the PTEN hamartoma tumor syndromes spectrum that also includes
CC       Cowden syndrome. Note=The disease is caused by variants affecting the
CC       gene represented in this entry.
CC   -!- DISEASE: Squamous cell carcinoma of the head and neck (HNSCC)
CC       [MIM:275355]: A non-melanoma skin cancer affecting the head and neck.
CC       The hallmark of cutaneous SCC is malignant transformation of normal
CC       epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of
CC       endometrium, the mucous lining of the uterus. Most endometrial cancers
CC       are adenocarcinomas, cancers that begin in cells that make and release
CC       mucus and other fluids. {ECO:0000269|PubMed:16506206}. Note=Disease
CC       susceptibility is associated with variants affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Note=PTEN mutations are found in a subset of patients with
CC       Proteus syndrome, a genetically heterogeneous condition. The molecular
CC       diagnosis of PTEN mutation positive cases classifies Proteus syndrome
CC       patients as part of the PTEN hamartoma syndrome spectrum. As such,
CC       patients surviving the early years of Proteus syndrome are likely at a
CC       greater risk of developing malignancies.
CC   -!- DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant
CC       central nervous system neoplasms derived from glial cells. They
CC       comprise astrocytomas and glioblastoma multiforme that are derived from
CC       astrocytes, oligodendrogliomas derived from oligodendrocytes and
CC       ependymomas derived from ependymocytes. {ECO:0000269|PubMed:12085208}.
CC       Note=Disease susceptibility is associated with variants affecting the
CC       gene represented in this entry.
CC   -!- DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in
CC       tissues of the prostate. Most prostate cancers are adenocarcinomas that
CC       develop in the acini of the prostatic ducts. Other rare histopathologic
CC       types of prostate cancer that occur in approximately 5% of patients
CC       include small cell carcinoma, mucinous carcinoma, prostatic ductal
CC       carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal
CC       cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell
CC       carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:26504226,
CC       ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated
CC       with variants affecting the gene represented in this entry.
CC   -!- DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients
CC       have autism spectrum disorders and macrocephaly, with head
CC       circumferences ranging from +2.5 to +8 SD for age and sex (average head
CC       circumference +4.0 SD). {ECO:0000269|PubMed:15805158,
CC       ECO:0000269|PubMed:23160955, ECO:0000269|PubMed:26637798}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and
CC       PTEN is a cause of chromosome 10q23 deletion syndrome, which shows
CC       overlapping features of the following three disorders: Bannayan-Zonana
CC       syndrome, Cowden disease and juvenile polyposis syndrome.
CC   -!- MISCELLANEOUS: [Isoform alpha]: Produced by alternative initiation at
CC       an upstream CTG start codon. May contain a signal peptide at positions
CC       1-21. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the PTEN phosphatase protein family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/158/PTEN";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U96180; AAB66902.1; -; mRNA.
DR   EMBL; U92436; AAC51182.1; -; mRNA.
DR   EMBL; U93051; AAC51183.1; -; mRNA.
DR   EMBL; AF143315; AAD38372.1; -; Genomic_DNA.
DR   EMBL; AF143312; AAD38372.1; JOINED; Genomic_DNA.
DR   EMBL; AF143313; AAD38372.1; JOINED; Genomic_DNA.
DR   EMBL; AF143314; AAD38372.1; JOINED; Genomic_DNA.
DR   EMBL; AF000734; AAC08699.1; -; Genomic_DNA.
DR   EMBL; AF000726; AAC08699.1; JOINED; Genomic_DNA.
DR   EMBL; AF000727; AAC08699.1; JOINED; Genomic_DNA.
DR   EMBL; AF000728; AAC08699.1; JOINED; Genomic_DNA.
DR   EMBL; AF000729; AAC08699.1; JOINED; Genomic_DNA.
DR   EMBL; AF000730; AAC08699.1; JOINED; Genomic_DNA.
DR   EMBL; AF000731; AAC08699.1; JOINED; Genomic_DNA.
DR   EMBL; AF000732; AAC08699.1; JOINED; Genomic_DNA.
DR   EMBL; AF000733; AAC08699.1; JOINED; Genomic_DNA.
DR   EMBL; AF067844; AAD13528.1; -; Genomic_DNA.
DR   EMBL; JF268690; ADZ48535.1; -; mRNA.
DR   EMBL; CR450306; CAG29302.1; -; mRNA.
DR   EMBL; AK313581; BAG36351.1; -; mRNA.
DR   EMBL; DQ073384; AAY57327.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW50174.1; -; Genomic_DNA.
DR   EMBL; BC005821; AAH05821.1; -; mRNA.
DR   CCDS; CCDS31238.1; -. [P60484-1]
DR   RefSeq; NP_000305.3; NM_000314.6. [P60484-1]
DR   RefSeq; NP_001291646.2; NM_001304717.2.
DR   RefSeq; NP_001291647.1; NM_001304718.1.
DR   PDB; 1D5R; X-ray; 2.10 A; A=8-353.
DR   PDB; 2KYL; NMR; -; B=391-403.
DR   PDB; 4O1V; X-ray; 2.00 A; B=354-368.
DR   PDB; 5BUG; X-ray; 2.40 A; A/B/C/D=14-351.
DR   PDB; 5BZX; X-ray; 2.50 A; A/B/C/D=14-351.
DR   PDB; 5BZZ; X-ray; 2.20 A; A/B/C/D=14-351.
DR   PDB; 7JTX; X-ray; 3.23 A; A=7-395.
DR   PDB; 7JUK; X-ray; 3.15 A; A=7-353, A=378-390.
DR   PDB; 7JUL; X-ray; 2.53 A; A=7-353, A=378-390.
DR   PDB; 7JVX; X-ray; 3.20 A; A=1-403.
DR   PDB; 7PC7; X-ray; 2.10 A; E/F=394-403.
DR   PDB; 8X3S; X-ray; 1.87 A; B=29-41.
DR   PDBsum; 1D5R; -.
DR   PDBsum; 2KYL; -.
DR   PDBsum; 4O1V; -.
DR   PDBsum; 5BUG; -.
DR   PDBsum; 5BZX; -.
DR   PDBsum; 5BZZ; -.
DR   PDBsum; 7JTX; -.
DR   PDBsum; 7JUK; -.
DR   PDBsum; 7JUL; -.
DR   PDBsum; 7JVX; -.
DR   PDBsum; 7PC7; -.
DR   PDBsum; 8X3S; -.
DR   AlphaFoldDB; P60484; -.
DR   SMR; P60484; -.
DR   BioGRID; 111700; 847.
DR   ComplexPortal; CPX-3153; PTEN phosphatase complex.
DR   CORUM; P60484; -.
DR   DIP; DIP-35019N; -.
DR   ELM; P60484; -.
DR   FunCoup; P60484; 3633.
DR   IntAct; P60484; 90.
DR   MINT; P60484; -.
DR   STRING; 9606.ENSP00000361021; -.
DR   BindingDB; P60484; -.
DR   ChEMBL; CHEMBL2052032; -.
DR   DrugBank; DB04327; Phosphatidylethanolamine.
DR   GuidetoPHARMACOLOGY; 2497; -.
DR   SwissLipids; SLP:000000849; -.
DR   TCDB; 1.A.51.2.4; the voltage-gated proton channel (vpc) family.
DR   CarbonylDB; P60484; -.
DR   DEPOD; PTEN; -.
DR   GlyGen; P60484; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; P60484; -.
DR   MetOSite; P60484; -.
DR   PhosphoSitePlus; P60484; -.
DR   BioMuta; PTEN; -.
DR   DMDM; 42560209; -.
DR   CPTAC; CPTAC-5746; -.
DR   CPTAC; CPTAC-5747; -.
DR   CPTAC; CPTAC-5748; -.
DR   CPTAC; non-CPTAC-5426; -.
DR   CPTAC; non-CPTAC-5429; -.
DR   CPTAC; non-CPTAC-5430; -.
DR   CPTAC; non-CPTAC-5566; -.
DR   CPTAC; non-CPTAC-5567; -.
DR   jPOST; P60484; -.
DR   MassIVE; P60484; -.
DR   PaxDb; 9606-ENSP00000361021; -.
DR   PeptideAtlas; P60484; -.
DR   ProteomicsDB; 57209; -. [P60484-1]
DR   Pumba; P60484; -.
DR   Antibodypedia; 3420; 1732 antibodies from 53 providers.
DR   CPTC; P60484; 8 antibodies.
DR   DNASU; 5728; -.
DR   Ensembl; ENST00000371953.8; ENSP00000361021.3; ENSG00000171862.16. [P60484-1]
DR   Ensembl; ENST00000644628.2; ENSP00000494918.2; ENSG00000284792.2. [P60484-1]
DR   Ensembl; ENST00000688308.1; ENSP00000508752.1; ENSG00000171862.16. [P60484-1]
DR   Ensembl; ENST00000710385.1; ENSP00000518242.1; ENSG00000284792.2. [P60484-1]
DR   Ensembl; ENST00000710387.1; ENSP00000518244.1; ENSG00000284792.2. [P60484-2]
DR   GeneID; 5728; -.
DR   KEGG; hsa:5728; -.
DR   MANE-Select; ENST00000371953.8; ENSP00000361021.3; NM_000314.8; NP_000305.3.
DR   UCSC; uc001kfb.4; human. [P60484-1]
DR   AGR; HGNC:9588; -.
DR   CTD; 5728; -.
DR   DisGeNET; 5728; -.
DR   GeneCards; PTEN; -.
DR   GeneReviews; PTEN; -.
DR   HGNC; HGNC:9588; PTEN.
DR   HPA; ENSG00000171862; Low tissue specificity.
DR   MalaCards; PTEN; -.
DR   MIM; 137800; phenotype.
DR   MIM; 158350; phenotype.
DR   MIM; 176807; phenotype.
DR   MIM; 275355; phenotype.
DR   MIM; 601728; gene.
DR   MIM; 605309; phenotype.
DR   MIM; 608089; phenotype.
DR   MIM; 612242; phenotype.
DR   MIM; 613028; phenotype.
DR   neXtProt; NX_P60484; -.
DR   OpenTargets; ENSG00000171862; -.
DR   Orphanet; 109; Bannayan-Riley-Ruvalcaba syndrome.
DR   Orphanet; 201; Cowden syndrome.
DR   Orphanet; 145; Hereditary breast and/or ovarian cancer syndrome.
DR   Orphanet; 79076; Juvenile polyposis of infancy.
DR   Orphanet; 65285; Lhermitte-Duclos disease.
DR   Orphanet; 210548; Macrocephaly-intellectual disability-autism syndrome.
DR   Orphanet; 2969; Proteus-like syndrome.
DR   Orphanet; 137608; Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome.
DR   Orphanet; 494547; Squamous cell carcinoma of the hypopharynx.
DR   Orphanet; 494550; Squamous cell carcinoma of the larynx.
DR   Orphanet; 502366; Squamous cell carcinoma of the lip.
DR   Orphanet; 500464; Squamous cell carcinoma of the nasal cavity and paranasal sinuses.
DR   Orphanet; 502363; Squamous cell carcinoma of the oral cavity.
DR   Orphanet; 500478; Squamous cell carcinoma of the oropharynx.
DR   PharmGKB; PA33942; -.
DR   VEuPathDB; HostDB:ENSG00000171862; -.
DR   eggNOG; KOG2283; Eukaryota.
DR   GeneTree; ENSGT00940000154335; -.
DR   HOGENOM; CLU_020105_5_2_1; -.
DR   InParanoid; P60484; -.
DR   OMA; CKKFKQR; -.
DR   OrthoDB; 16692at2759; -.
DR   PAN-GO; P60484; 12 GO annotations based on evolutionary models.
DR   PhylomeDB; P60484; -.
DR   TreeFam; TF324513; -.
DR   BioCyc; MetaCyc:HS10404-MONOMER; -.
DR   BRENDA; 3.1.3.16; 2681.
DR   BRENDA; 3.1.3.67; 2681.
DR   PathwayCommons; P60484; -.
DR   Reactome; R-HSA-1660499; Synthesis of PIPs at the plasma membrane.
DR   Reactome; R-HSA-1855204; Synthesis of IP3 and IP4 in the cytosol.
DR   Reactome; R-HSA-199418; Negative regulation of the PI3K/AKT network.
DR   Reactome; R-HSA-202424; Downstream TCR signaling.
DR   Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes.
DR   Reactome; R-HSA-5674404; PTEN Loss of Function in Cancer.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   Reactome; R-HSA-5689896; Ovarian tumor domain proteases.
DR   Reactome; R-HSA-8943723; Regulation of PTEN mRNA translation.
DR   Reactome; R-HSA-8948747; Regulation of PTEN localization.
DR   Reactome; R-HSA-8948751; Regulation of PTEN stability and activity.
DR   Reactome; R-HSA-8986944; Transcriptional Regulation by MECP2.
DR   SignaLink; P60484; -.
DR   SIGNOR; P60484; -.
DR   BioGRID-ORCS; 5728; 85 hits in 1159 CRISPR screens.
DR   CD-CODE; 8C2F96ED; Centrosome.
DR   CD-CODE; B5B9A610; PML body.
DR   ChiTaRS; PTEN; human.
DR   EvolutionaryTrace; P60484; -.
DR   GeneWiki; PTEN_(gene); -.
DR   GenomeRNAi; 5728; -.
DR   Pharos; P60484; Tchem.
DR   PRO; PR:P60484; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   RNAct; P60484; protein.
DR   Bgee; ENSG00000171862; Expressed in sperm and 191 other cell types or tissues.
DR   ExpressionAtlas; P60484; baseline and differential.
DR   GO; GO:0016324; C:apical plasma membrane; IMP:UniProtKB.
DR   GO; GO:0042995; C:cell projection; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0009898; C:cytoplasmic side of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0043197; C:dendritic spine; IEA:UniProtKB-SubCell.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0035749; C:myelin sheath adaxonal region; ISS:BHF-UCL.
DR   GO; GO:0043005; C:neuron projection; ISS:BHF-UCL.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0016605; C:PML body; IEA:UniProtKB-SubCell.
DR   GO; GO:0014069; C:postsynaptic density; IEA:UniProtKB-SubCell.
DR   GO; GO:0043220; C:Schmidt-Lanterman incisure; ISS:BHF-UCL.
DR   GO; GO:0010997; F:anaphase-promoting complex binding; IPI:BHF-UCL.
DR   GO; GO:0008013; F:beta-catenin binding; IPI:BHF-UCL.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0030351; F:inositol-1,3,4,5,6-pentakisphosphate 3-phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0051717; F:inositol-1,3,4,5-tetrakisphosphate 3-phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0008289; F:lipid binding; IEA:UniProtKB-KW.
DR   GO; GO:0140678; F:molecular function inhibitor activity; IMP:DisProt.
DR   GO; GO:0030165; F:PDZ domain binding; IPI:UniProtKB.
DR   GO; GO:0052866; F:phosphatidylinositol phosphate phosphatase activity; IDA:UniProt.
DR   GO; GO:0016314; F:phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0051800; F:phosphatidylinositol-3,4-bisphosphate 3-phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0004438; F:phosphatidylinositol-3-phosphate phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0004721; F:phosphoprotein phosphatase activity; IDA:BHF-UCL.
DR   GO; GO:0004722; F:protein serine/threonine phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0004725; F:protein tyrosine phosphatase activity; IDA:UniProtKB.
DR   GO; GO:1990757; F:ubiquitin ligase activator activity; ISS:BHF-UCL.
DR   GO; GO:1990381; F:ubiquitin-specific protease binding; IPI:MGI.
DR   GO; GO:0030534; P:adult behavior; ISS:BHF-UCL.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0016477; P:cell migration; ISS:UniProtKB.
DR   GO; GO:0048870; P:cell motility; IBA:GO_Central.
DR   GO; GO:0071257; P:cellular response to electrical stimulus; IMP:BHF-UCL.
DR   GO; GO:0007417; P:central nervous system development; ISS:UniProtKB.
DR   GO; GO:0032286; P:central nervous system myelin maintenance; ISS:BHF-UCL.
DR   GO; GO:0021955; P:central nervous system neuron axonogenesis; ISS:BHF-UCL.
DR   GO; GO:0060997; P:dendritic spine morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0021542; P:dentate gyrus development; ISS:BHF-UCL.
DR   GO; GO:0048853; P:forebrain morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0007507; P:heart development; ISS:UniProtKB.
DR   GO; GO:0007611; P:learning or memory; ISS:BHF-UCL.
DR   GO; GO:0045475; P:locomotor rhythm; ISS:BHF-UCL.
DR   GO; GO:0007626; P:locomotory behavior; ISS:BHF-UCL.
DR   GO; GO:0042711; P:maternal behavior; ISS:BHF-UCL.
DR   GO; GO:0033555; P:multicellular organismal response to stress; ISS:BHF-UCL.
DR   GO; GO:0050771; P:negative regulation of axonogenesis; ISS:BHF-UCL.
DR   GO; GO:1902807; P:negative regulation of cell cycle G1/S phase transition; IDA:UniProtKB.
DR   GO; GO:0030336; P:negative regulation of cell migration; IMP:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:BHF-UCL.
DR   GO; GO:0045792; P:negative regulation of cell size; ISS:BHF-UCL.
DR   GO; GO:2000773; P:negative regulation of cellular senescence; ISS:BHF-UCL.
DR   GO; GO:0010719; P:negative regulation of epithelial to mesenchymal transition; IMP:BHF-UCL.
DR   GO; GO:0090394; P:negative regulation of excitatory postsynaptic potential; ISS:BHF-UCL.
DR   GO; GO:0051895; P:negative regulation of focal adhesion assembly; IMP:UniProtKB.
DR   GO; GO:2000134; P:negative regulation of G1/S transition of mitotic cell cycle; IDA:BHF-UCL.
DR   GO; GO:0051548; P:negative regulation of keratinocyte migration; IMP:BHF-UCL.
DR   GO; GO:0010977; P:negative regulation of neuron projection development; ISS:ARUK-UCL.
DR   GO; GO:0046621; P:negative regulation of organ growth; ISS:BHF-UCL.
DR   GO; GO:0045668; P:negative regulation of osteoblast differentiation; IDA:UniProt.
DR   GO; GO:0033137; P:negative regulation of peptidyl-serine phosphorylation; IMP:UniProtKB.
DR   GO; GO:0051898; P:negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IDA:UniProt.
DR   GO; GO:2000808; P:negative regulation of synaptic vesicle clustering; ISS:BHF-UCL.
DR   GO; GO:1904706; P:negative regulation of vascular associated smooth muscle cell proliferation; IMP:BHF-UCL.
DR   GO; GO:1903690; P:negative regulation of wound healing, spreading of epidermal cells; IMP:BHF-UCL.
DR   GO; GO:0007270; P:neuron-neuron synaptic transmission; ISS:BHF-UCL.
DR   GO; GO:0043491; P:phosphatidylinositol 3-kinase/protein kinase B signal transduction; IBA:GO_Central.
DR   GO; GO:0006661; P:phosphatidylinositol biosynthetic process; TAS:Reactome.
DR   GO; GO:0046856; P:phosphatidylinositol dephosphorylation; IDA:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; ISS:BHF-UCL.
DR   GO; GO:2000463; P:positive regulation of excitatory postsynaptic potential; ISS:BHF-UCL.
DR   GO; GO:1902533; P:positive regulation of intracellular signal transduction; IMP:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:BHF-UCL.
DR   GO; GO:2000060; P:positive regulation of ubiquitin-dependent protein catabolic process; IDA:BHF-UCL.
DR   GO; GO:0097107; P:postsynaptic density assembly; ISS:BHF-UCL.
DR   GO; GO:0060134; P:prepulse inhibition; ISS:BHF-UCL.
DR   GO; GO:0097105; P:presynaptic membrane assembly; ISS:BHF-UCL.
DR   GO; GO:0006470; P:protein dephosphorylation; IDA:UniProtKB.
DR   GO; GO:0050821; P:protein stabilization; IDA:BHF-UCL.
DR   GO; GO:0010975; P:regulation of neuron projection development; ISS:UniProtKB.
DR   GO; GO:0051896; P:regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IBA:GO_Central.
DR   GO; GO:0031647; P:regulation of protein stability; IMP:UniProtKB.
DR   GO; GO:0060024; P:rhythmic synaptic transmission; ISS:BHF-UCL.
DR   GO; GO:0035176; P:social behavior; ISS:BHF-UCL.
DR   GO; GO:0007056; P:spindle assembly involved in female meiosis; IDA:UniProt.
DR   GO; GO:0007416; P:synapse assembly; ISS:BHF-UCL.
DR   GO; GO:0060074; P:synapse maturation; ISS:BHF-UCL.
DR   CDD; cd14509; PTP_PTEN; 1.
DR   FunFam; 2.60.40.1110:FF:000003; Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN; 1.
DR   FunFam; 3.90.190.10:FF:000029; Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN; 1.
DR   Gene3D; 2.60.40.1110; -; 1.
DR   Gene3D; 3.90.190.10; Protein tyrosine phosphatase superfamily; 1.
DR   InterPro; IPR017361; Bifunc_PIno_P3_Pase/Pase_PTEN.
DR   InterPro; IPR035892; C2_domain_sf.
DR   InterPro; IPR051281; Dual-spec_lipid-protein_phosph.
DR   InterPro; IPR029021; Prot-tyrosine_phosphatase-like.
DR   InterPro; IPR045101; PTP_PTEN.
DR   InterPro; IPR014020; Tensin_C2-dom.
DR   InterPro; IPR029023; Tensin_phosphatase.
DR   InterPro; IPR016130; Tyr_Pase_AS.
DR   InterPro; IPR003595; Tyr_Pase_cat.
DR   InterPro; IPR000387; Tyr_Pase_dom.
DR   PANTHER; PTHR12305; PHOSPHATASE WITH HOMOLOGY TO TENSIN; 1.
DR   PANTHER; PTHR12305:SF81; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE 3-PHOSPHATASE AND DUAL-SPECIFICITY PROTEIN PHOSPHATASE PTEN; 1.
DR   Pfam; PF10409; PTEN_C2; 1.
DR   Pfam; PF22785; Tc-R-P; 1.
DR   PIRSF; PIRSF038025; PTEN; 1.
DR   SMART; SM01326; PTEN_C2; 1.
DR   SMART; SM00404; PTPc_motif; 1.
DR   SMART; SM01301; PTPlike_phytase; 1.
DR   SUPFAM; SSF52799; (Phosphotyrosine protein) phosphatases II; 1.
DR   SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 1.
DR   PROSITE; PS51182; C2_TENSIN; 1.
DR   PROSITE; PS51181; PPASE_TENSIN; 1.
DR   PROSITE; PS50056; TYR_PHOSPHATASE_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative initiation; Alternative splicing;
KW   Apoptosis; Autism spectrum disorder; Cell projection; Cytoplasm;
KW   Disease variant; Hydrolase; Isopeptide bond; Lipid metabolism;
KW   Lipid-binding; Neurogenesis; Nucleus; Phosphoprotein; Protein phosphatase;
KW   Proteomics identification; Reference proteome; Secreted; Synapse;
KW   Tumor suppressor; Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0007744|PubMed:22814378"
FT   CHAIN           2..403
FT                   /note="Phosphatidylinositol 3,4,5-trisphosphate 3-
FT                   phosphatase and dual-specificity protein phosphatase PTEN"
FT                   /id="PRO_0000215904"
FT   DOMAIN          14..185
FT                   /note="Phosphatase tensin-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00590"
FT   DOMAIN          190..350
FT                   /note="C2 tensin-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00589"
FT   REGION          338..348
FT                   /note="Required for interaction with NOP53"
FT                   /evidence="ECO:0000269|PubMed:15355975"
FT   REGION          352..403
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           401..403
FT                   /note="PDZ domain-binding"
FT                   /evidence="ECO:0000250|UniProtKB:O08586"
FT   COMPBIAS        360..369
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        383..393
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        124
FT                   /note="Phosphocysteine intermediate"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00590"
FT   MOD_RES         2
FT                   /note="N-acetylthreonine"
FT                   /evidence="ECO:0007744|PubMed:22814378"
FT   MOD_RES         294
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O08586"
FT   MOD_RES         319
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:26166433"
FT   MOD_RES         321
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:26166433"
FT   MOD_RES         336
FT                   /note="Phosphotyrosine; by FRK"
FT                   /evidence="ECO:0000269|PubMed:19345329"
FT   MOD_RES         366
FT                   /note="Phosphothreonine; by GSK3-beta and PLK3"
FT                   /evidence="ECO:0000269|PubMed:12297295,
FT                   ECO:0000269|PubMed:20940307, ECO:0007744|PubMed:24275569"
FT   MOD_RES         370
FT                   /note="Phosphoserine; by CK2 and PLK3"
FT                   /evidence="ECO:0000269|PubMed:11035045,
FT                   ECO:0000269|PubMed:12297295, ECO:0000269|PubMed:20940307"
FT   MOD_RES         380
FT                   /note="Phosphoserine; by ROCK1 and CK2"
FT                   /evidence="ECO:0000269|PubMed:11035045"
FT   MOD_RES         382
FT                   /note="Phosphothreonine; by ROCK1 and CK2"
FT                   /evidence="ECO:0000269|PubMed:11035045"
FT   MOD_RES         383
FT                   /note="Phosphothreonine; by ROCK1 and CK2"
FT                   /evidence="ECO:0000269|PubMed:11035045"
FT   MOD_RES         385
FT                   /note="Phosphoserine; by CK2"
FT                   /evidence="ECO:0000269|PubMed:11035045,
FT                   ECO:0000269|PubMed:12297295"
FT   MOD_RES         401
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:10646847"
FT   CROSSLNK        13
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:18716620"
FT   CROSSLNK        289
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:18716620"
FT   VAR_SEQ         1
FT                   /note="M -> MERGGEAAAAAAAAAAAPGRGSESPVTISRAGNAGELVSPLLLPPTR
FT                   RRRRRHIQGPGPVLNLPSAAAAPPVARAPEAAGGGSRSEDYSSSPHSAAAAARPLAAEE
FT                   KQAQSLQPSSSRRSSHYPAAVQSQAAAERGASATAKSRAISILQKKPRHQQLLPSLSSF
FT                   FFSHRLPDM (in isoform alpha)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_055420"
FT   VAR_SEQ         55..70
FT                   /note="RFLDSKHKNHYKIYNL -> S (in isoform 3)"
FT                   /evidence="ECO:0000303|Ref.7"
FT                   /id="VSP_055421"
FT   VAR_SEQ         165..190
FT                   /note="GVTIPSQRRYVYYYSYLLKNHLDYRP -> ADPTGGIPDKGIIVIGDGSSMD
FT                   VIAP (in isoform 3)"
FT                   /evidence="ECO:0000303|Ref.7"
FT                   /id="VSP_055422"
FT   VAR_SEQ         191..403
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|Ref.7"
FT                   /id="VSP_055423"
FT   VARIANT         10
FT                   /note="S -> N (retains phosphatase activity towards
FT                   Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; retains the ability to
FT                   bind phospholipid membranes)"
FT                   /evidence="ECO:0000269|PubMed:10866302"
FT                   /id="VAR_026248"
FT   VARIANT         15
FT                   /note="R -> S (in CWS1; also found in glioma;
FT                   dbSNP:rs1064794096)"
FT                   /evidence="ECO:0000269|PubMed:21659347,
FT                   ECO:0000269|PubMed:9090379"
FT                   /id="VAR_007457"
FT   VARIANT         16
FT                   /note="Y -> C (loss of phosphatase activity towards
FT                   Ins(1,3,4,5)P4; retains the ability to bind phospholipid
FT                   membranes)"
FT                   /evidence="ECO:0000269|PubMed:10866302"
FT                   /id="VAR_026249"
FT   VARIANT         19
FT                   /note="D -> N (in malignant melanoma; somatic mutation;
FT                   dbSNP:rs121909233)"
FT                   /evidence="ECO:0000269|PubMed:10978354"
FT                   /id="VAR_018100"
FT   VARIANT         20
FT                   /note="G -> E (reduced phosphatase activity towards
FT                   Ins(1,3,4,5)P4; retains phosphatase activity towards
FT                   PtdIns(3,4,5)P3; dbSNP:rs1064795967)"
FT                   /evidence="ECO:0000269|PubMed:10866302"
FT                   /id="VAR_026250"
FT   VARIANT         27
FT                   /note="Y -> S (loss of phosphatase activity towards
FT                   Ins(1,3,4,5)P4; dbSNP:rs886041877)"
FT                   /evidence="ECO:0000269|PubMed:10866302"
FT                   /id="VAR_026251"
FT   VARIANT         33
FT                   /note="Missing (in CWS1; dbSNP:rs1554893765)"
FT                   /evidence="ECO:0000269|PubMed:10234502"
FT                   /id="VAR_008733"
FT   VARIANT         34
FT                   /note="A -> D (in CWS1)"
FT                   /evidence="ECO:0000269|PubMed:10400993,
FT                   ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:21659347"
FT                   /id="VAR_008734"
FT   VARIANT         35
FT                   /note="M -> R (in CWS1; dbSNP:rs121909225)"
FT                   /evidence="ECO:0000269|PubMed:9425889"
FT                   /id="VAR_008036"
FT   VARIANT         36
FT                   /note="G -> E (in ENDMC; also found in glioma;
FT                   dbSNP:rs1554893792)"
FT                   /evidence="ECO:0000269|PubMed:16506206,
FT                   ECO:0000269|PubMed:9090379"
FT                   /id="VAR_007458"
FT   VARIANT         36
FT                   /note="G -> R (in CWS1; also found in a patient with
FT                   endometrial hyperplasia; dbSNP:rs786204854)"
FT                   /evidence="ECO:0000269|PubMed:10772390,
FT                   ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9635567"
FT                   /id="VAR_026252"
FT   VARIANT         42
FT                   /note="L -> R (in glioma; retains phosphatase activity
FT                   towards Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; retains the
FT                   ability to bind phospholipid membranes)"
FT                   /evidence="ECO:0000269|PubMed:9090379"
FT                   /id="VAR_007459"
FT   VARIANT         47
FT                   /note="R -> G (in CWS1; dbSNP:rs786204855)"
FT                   /evidence="ECO:0000269|PubMed:11494117"
FT                   /id="VAR_011587"
FT   VARIANT         57
FT                   /note="L -> W (in glioma; likely pathogenic; loss of
FT                   protein phosphatase activity; dbSNP:rs786202398)"
FT                   /evidence="ECO:0000269|PubMed:9090379,
FT                   ECO:0000269|PubMed:9256433"
FT                   /id="VAR_007460"
FT   VARIANT         61
FT                   /note="H -> D (found in a patient with congenital cardiac
FT                   disease, macrocephaly, ventriculomegaly, skeletal defects,
FT                   anal atresia, tracheoesophageal fistula, renal anomalies;
FT                   likely pathogenic; dbSNP:rs121909236)"
FT                   /evidence="ECO:0000269|PubMed:11748304"
FT                   /id="VAR_018101"
FT   VARIANT         61
FT                   /note="H -> R (in CWS1; loss of phosphatase activity
FT                   towards Ins(1,3,4,5)P4; dbSNP:rs398123316)"
FT                   /evidence="ECO:0000269|PubMed:10866302,
FT                   ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:24778394"
FT                   /id="VAR_026253"
FT   VARIANT         65..403
FT                   /note="Missing (in MCEPHAS)"
FT                   /evidence="ECO:0000269|PubMed:26637798"
FT                   /id="VAR_078705"
FT   VARIANT         67
FT                   /note="I -> R (in CWS1)"
FT                   /evidence="ECO:0000269|PubMed:9467011"
FT                   /id="VAR_007461"
FT   VARIANT         68
FT                   /note="Y -> H (in CWS1; loss of phosphatase activity
FT                   towards Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; retains the
FT                   ability to bind phospholipid membranes; dbSNP:rs398123317)"
FT                   /evidence="ECO:0000269|PubMed:10400993,
FT                   ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:11494117,
FT                   ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9600246"
FT                   /id="VAR_007462"
FT   VARIANT         70
FT                   /note="L -> P (in CWS1; dbSNP:rs121909226)"
FT                   /evidence="ECO:0000269|PubMed:9832031"
FT                   /id="VAR_018102"
FT   VARIANT         71
FT                   /note="C -> Y (in CWS1; loss of phosphatase activity
FT                   towards Ins(1,3,4,5)P4)"
FT                   /evidence="ECO:0000269|PubMed:10866302"
FT                   /id="VAR_026254"
FT   VARIANT         93
FT                   /note="H -> R (in MCEPHAS; dbSNP:rs121909238)"
FT                   /evidence="ECO:0000269|PubMed:15805158"
FT                   /id="VAR_032634"
FT   VARIANT         93
FT                   /note="H -> Y (in CWS1; dbSNP:rs786204927)"
FT                   /evidence="ECO:0000269|PubMed:10866302,
FT                   ECO:0000269|PubMed:24778394"
FT                   /id="VAR_026255"
FT   VARIANT         105
FT                   /note="C -> F (in CWS1; loss of phosphatase activity
FT                   towards Ins(1,3,4,5)P4)"
FT                   /evidence="ECO:0000269|PubMed:10866302"
FT                   /id="VAR_026256"
FT   VARIANT         105
FT                   /note="C -> Y (in CWS1; dbSNP:rs587782343)"
FT                   /evidence="ECO:0000269|PubMed:10400993,
FT                   ECO:0000269|PubMed:11494117"
FT                   /id="VAR_008735"
FT   VARIANT         107
FT                   /note="D -> Y (in CWS1; also found in glioblastoma; loss of
FT                   phosphatase activity towards Ins(1,3,4,5)P4;
FT                   dbSNP:rs57374291)"
FT                   /evidence="ECO:0000269|PubMed:10866302,
FT                   ECO:0000269|PubMed:9331071"
FT                   /id="VAR_026257"
FT   VARIANT         112
FT                   /note="L -> P (in CWS1 and LDD; loss of phosphatase
FT                   activity towards Ins(1,3,4,5)P4; dbSNP:rs121909230)"
FT                   /evidence="ECO:0000269|PubMed:10051160,
FT                   ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:9600246"
FT                   /id="VAR_007807"
FT   VARIANT         112
FT                   /note="L -> R (loss of phosphatase activity towards
FT                   Ins(1,3,4,5)P4)"
FT                   /evidence="ECO:0000269|PubMed:10866302"
FT                   /id="VAR_026258"
FT   VARIANT         119
FT                   /note="V -> L (in multiple cancers; dbSNP:rs139767111)"
FT                   /evidence="ECO:0000269|PubMed:10807691"
FT                   /id="VAR_011588"
FT   VARIANT         121
FT                   /note="A -> G (in HNSCC; dbSNP:rs121909237)"
FT                   /evidence="ECO:0000269|PubMed:11801303"
FT                   /id="VAR_018103"
FT   VARIANT         121
FT                   /note="A -> P (in glioblastoma; loss of phosphatase
FT                   activity towards Ins(1,3,4,5)P4)"
FT                   /evidence="ECO:0000269|PubMed:10866302,
FT                   ECO:0000269|PubMed:9331071"
FT                   /id="VAR_026259"
FT   VARIANT         123
FT                   /note="H -> R (in CWS1; dbSNP:rs121909222)"
FT                   /evidence="ECO:0000269|PubMed:10234502,
FT                   ECO:0000269|PubMed:9259288"
FT                   /id="VAR_007463"
FT   VARIANT         123
FT                   /note="H -> Y (in endometrial cancer; loss of protein
FT                   phosphatase activity; dbSNP:rs786204931)"
FT                   /evidence="ECO:0000269|PubMed:9256433"
FT                   /id="VAR_026260"
FT   VARIANT         124
FT                   /note="C -> R (in CWS1; dbSNP:rs121909223)"
FT                   /evidence="ECO:0000269|PubMed:10234502,
FT                   ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:9259288"
FT                   /id="VAR_007464"
FT   VARIANT         124
FT                   /note="C -> S (in CWS1; phosphatase-dead protein with
FT                   neither lipid nor protein phosphatase activity; loss of
FT                   phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase
FT                   activity; dbSNP:rs121909223)"
FT                   /evidence="ECO:0000269|PubMed:11230179,
FT                   ECO:0000269|PubMed:9593664, ECO:0000269|PubMed:9811831"
FT                   /id="VAR_018104"
FT   VARIANT         126
FT                   /note="A -> G (in a patient with prostate cancer; reduced
FT                   phosphatase activity towards PtdIns(3,4,5); shifts its
FT                   activity from phosphatidylinositol phosphate 3-phosphatase
FT                   to phosphatidylinositol phosphate 5-phosphatase; disrupts
FT                   PI3K/ATK signaling; reduced cell migration)"
FT                   /evidence="ECO:0000269|PubMed:26504226"
FT                   /id="VAR_076551"
FT   VARIANT         129
FT                   /note="G -> E (in CWS1; no lipid phosphatase activity but
FT                   retains protein phosphatase activity; retains ability to
FT                   inhibit focal adhesion formation; dbSNP:rs121909218)"
FT                   /evidence="ECO:0000269|PubMed:10866302,
FT                   ECO:0000269|PubMed:11230179, ECO:0000269|PubMed:21659347,
FT                   ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9616126,
FT                   ECO:0000269|PubMed:9811831"
FT                   /id="VAR_007465"
FT   VARIANT         129
FT                   /note="G -> R (in glioblastoma; severely reduced protein
FT                   phosphatase activity; loss of phosphatase activity towards
FT                   Ins(1,3,4,5)P4; dbSNP:rs786204929)"
FT                   /evidence="ECO:0000269|PubMed:10866302,
FT                   ECO:0000269|PubMed:9072974, ECO:0000269|PubMed:9256433,
FT                   ECO:0000269|PubMed:9331071"
FT                   /id="VAR_007466"
FT   VARIANT         130
FT                   /note="R -> G (in CWS1; loss of phosphatase activity
FT                   towards Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3;
FT                   dbSNP:rs121909224)"
FT                   /evidence="ECO:0000269|PubMed:10866302,
FT                   ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:24778394"
FT                   /id="VAR_026261"
FT   VARIANT         130
FT                   /note="R -> L (in CWS1; also found in endometrial
FT                   hyperplasia; loss of phosphatase activity towards
FT                   Ins(1,3,4,5)P4; retains ability to bind phospholipid
FT                   membranes; dbSNP:rs121909229)"
FT                   /evidence="ECO:0000269|PubMed:10866302,
FT                   ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:24778394,
FT                   ECO:0000269|PubMed:9635567"
FT                   /id="VAR_007467"
FT   VARIANT         130
FT                   /note="R -> Q (in CWS1; loss of phosphatase activity
FT                   towards Ins(1,3,4,5)P4; retains ability to bind
FT                   phospholipid membranes; dbSNP:rs121909229)"
FT                   /evidence="ECO:0000269|PubMed:10866302,
FT                   ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:24778394,
FT                   ECO:0000269|PubMed:9915974"
FT                   /id="VAR_007468"
FT   VARIANT         131
FT                   /note="T -> I (in MCEPHAS; dbSNP:rs397514560)"
FT                   /evidence="ECO:0000269|PubMed:23160955"
FT                   /id="VAR_076762"
FT   VARIANT         132
FT                   /note="G -> V (in one patient with clinical findings
FT                   suggesting hamartoma tumor syndrome; dbSNP:rs121909241)"
FT                   /evidence="ECO:0000269|PubMed:16752378"
FT                   /id="VAR_032635"
FT   VARIANT         133
FT                   /note="V -> I (loss of phosphatase activity towards
FT                   Ins(1,3,4,5)P3)"
FT                   /evidence="ECO:0000269|PubMed:10866302"
FT                   /id="VAR_026262"
FT   VARIANT         134
FT                   /note="M -> L (in prostate cancer; no effect on protein
FT                   phosphatase activity; reduced phosphatase activity towards
FT                   Ins(1,3,4,5)P3 but retains PtdIns(3,4,5)P3 phosphatase
FT                   activity)"
FT                   /evidence="ECO:0000269|PubMed:10866302,
FT                   ECO:0000269|PubMed:9072974, ECO:0000269|PubMed:9256433"
FT                   /id="VAR_007469"
FT   VARIANT         135
FT                   /note="I -> V (in CWS1; dbSNP:rs587782360)"
FT                   /evidence="ECO:0000269|PubMed:10400993,
FT                   ECO:0000269|PubMed:11494117"
FT                   /id="VAR_008736"
FT   VARIANT         136
FT                   /note="C -> Y (in CWS1; loss of phosphatase activity
FT                   towards Ins(1,3,4,5)P3; dbSNP:rs786204859)"
FT                   /evidence="ECO:0000269|PubMed:10866302,
FT                   ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9735393"
FT                   /id="VAR_007808"
FT   VARIANT         137
FT                   /note="A -> AN (in CWS1)"
FT                   /evidence="ECO:0000269|PubMed:9345101"
FT                   /id="VAR_008737"
FT   VARIANT         155
FT                   /note="Y -> C (in CWS1; loss of phosphatase activity
FT                   towards Ins(1,3,4,5)P4; dbSNP:rs1060500126)"
FT                   /evidence="ECO:0000269|PubMed:10866302"
FT                   /id="VAR_026263"
FT   VARIANT         158
FT                   /note="V -> L (in multiple cancers)"
FT                   /evidence="ECO:0000269|PubMed:10807691"
FT                   /id="VAR_011589"
FT   VARIANT         165
FT                   /note="G -> E (in CWS1)"
FT                   /evidence="ECO:0000269|PubMed:10234502"
FT                   /id="VAR_008739"
FT   VARIANT         165
FT                   /note="G -> R (in CWS1; also found in glioblastoma;
FT                   severely reduced protein phosphatase activity; loss of
FT                   phosphatase activity towards Ins(1,3,4,5)P4; retains
FT                   ability to bind phospholipid membranes; dbSNP:rs587782603)"
FT                   /evidence="ECO:0000269|PubMed:10866302,
FT                   ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9256433,
FT                   ECO:0000269|PubMed:9331071"
FT                   /id="VAR_026264"
FT   VARIANT         165
FT                   /note="G -> V (in CWS1; dbSNP:rs786204863)"
FT                   /evidence="ECO:0000269|PubMed:9467011"
FT                   /id="VAR_008738"
FT   VARIANT         167
FT                   /note="T -> N (in MCEPHAS; dbSNP:rs397514559)"
FT                   /evidence="ECO:0000269|PubMed:23160955"
FT                   /id="VAR_076763"
FT   VARIANT         167
FT                   /note="T -> P (in breast cancer; severely reduced protein
FT                   phosphatase activity)"
FT                   /evidence="ECO:0000269|PubMed:9256433"
FT                   /id="VAR_026265"
FT   VARIANT         170
FT                   /note="S -> N (loss of phosphatase activity towards
FT                   Ins(1,3,4,5)P4; retains ability to bind phospholipid
FT                   membranes)"
FT                   /evidence="ECO:0000269|PubMed:10866302"
FT                   /id="VAR_026266"
FT   VARIANT         170
FT                   /note="S -> R (in CWS1; severely reduced protein
FT                   phosphatase activity; loss of phosphatase activity towards
FT                   Ins(1,3,4,5)P4; dbSNP:rs121909221)"
FT                   /evidence="ECO:0000269|PubMed:10400993,
FT                   ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:11494117,
FT                   ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9241266,
FT                   ECO:0000269|PubMed:9256433"
FT                   /id="VAR_007470"
FT   VARIANT         173
FT                   /note="R -> C (in CWS1; also found in endometrial
FT                   hyperplasia; loss of phosphatase activity towards
FT                   Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; retains ability to bind
FT                   phospholipid membranes; dbSNP:rs121913293)"
FT                   /evidence="ECO:0000269|PubMed:10866302,
FT                   ECO:0000269|PubMed:24778394, ECO:0000269|PubMed:9635567"
FT                   /id="VAR_026267"
FT   VARIANT         173
FT                   /note="R -> H (loss of phosphatase activity towards
FT                   Ins(1,3,4,5)P4; dbSNP:rs121913294)"
FT                   /evidence="ECO:0000269|PubMed:10866302"
FT                   /id="VAR_026268"
FT   VARIANT         173
FT                   /note="R -> P (loss of phosphatase activity towards
FT                   Ins(1,3,4,5)P4; dbSNP:rs121913294)"
FT                   /evidence="ECO:0000269|PubMed:10866302"
FT                   /id="VAR_026269"
FT   VARIANT         174
FT                   /note="Y -> N (found in a thyroid tumor; somatic variant;
FT                   loss of phosphatase activity towards Ins(1,3,4,5)P4;
FT                   dbSNP:rs587782316)"
FT                   /evidence="ECO:0000269|PubMed:10866302,
FT                   ECO:0000269|PubMed:39316756"
FT                   /id="VAR_026270"
FT   VARIANT         191
FT                   /note="V -> A (in endometrial hyperplasia)"
FT                   /evidence="ECO:0000269|PubMed:9635567"
FT                   /id="VAR_026271"
FT   VARIANT         217
FT                   /note="V -> I (in malignant melanoma; somatic mutation;
FT                   dbSNP:rs121909234)"
FT                   /evidence="ECO:0000269|PubMed:10978354"
FT                   /id="VAR_018105"
FT   VARIANT         227
FT                   /note="S -> F (reduced phosphatase activity towards
FT                   Ins(1,3,4,5)P4; retains PtdIns(3,4,5)P3 phosphatase
FT                   activity; dbSNP:rs905615413)"
FT                   /evidence="ECO:0000269|PubMed:10866302"
FT                   /id="VAR_026272"
FT   VARIANT         234
FT                   /note="R -> Q (in GLM2; uncertain significance; not capable
FT                   of inducing apoptosis; induced increased cell
FT                   proliferation; led to high constitutive AKT1 activation
FT                   which could not be increased further by stimulation with
FT                   insulin; dbSNP:rs121909235)"
FT                   /evidence="ECO:0000269|PubMed:12085208"
FT                   /id="VAR_018106"
FT   VARIANT         241
FT                   /note="F -> S (in MCEPHAS; dbSNP:rs121909240)"
FT                   /evidence="ECO:0000269|PubMed:15805158"
FT                   /id="VAR_032636"
FT   VARIANT         246
FT                   /note="P -> L (in CWS1; dbSNP:rs587782350)"
FT                   /evidence="ECO:0000269|PubMed:10400993"
FT                   /id="VAR_008740"
FT   VARIANT         251
FT                   /note="G -> C (loss of phosphatase activity towards
FT                   Ins(1,3,4,5)P4; retains ability to bind phospholipid
FT                   membranes)"
FT                   /evidence="ECO:0000269|PubMed:10866302"
FT                   /id="VAR_026273"
FT   VARIANT         252
FT                   /note="D -> G (in MCEPHAS and CWS1; dbSNP:rs121909239)"
FT                   /evidence="ECO:0000269|PubMed:15805158,
FT                   ECO:0000269|PubMed:21659347"
FT                   /id="VAR_032637"
FT   VARIANT         289
FT                   /note="K -> E (in CWS1; reduced phosphatase activity
FT                   towards Ins(1,3,4,5)P4; retains ability to bind
FT                   phospholipid membranes; predominantly nuclear;
FT                   dbSNP:rs562015640)"
FT                   /evidence="ECO:0000269|PubMed:10866302,
FT                   ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:9797362"
FT                   /id="VAR_008741"
FT   VARIANT         290
FT                   /note="V -> L (in dbSNP:rs35600253)"
FT                   /evidence="ECO:0000269|Ref.10"
FT                   /id="VAR_025167"
FT   VARIANT         319
FT                   /note="Missing (in glioma; reduced tumor suppressor
FT                   activity; fails to inactivate AKT/PKB)"
FT                   /evidence="ECO:0000269|PubMed:10468583,
FT                   ECO:0000269|PubMed:9090379"
FT                   /id="VAR_026274"
FT   VARIANT         331
FT                   /note="D -> G (in CWS1; reduced phosphatase activity
FT                   towards Ins(1,3,4,5)P4; retains ability to bind
FT                   phospholipid membranes)"
FT                   /evidence="ECO:0000269|PubMed:10866302"
FT                   /id="VAR_026275"
FT   VARIANT         341
FT                   /note="F -> V (in CWS1; loss of interaction with NOP53;
FT                   decreased phosphorylation at S-380; decreased stability;
FT                   loss of phosphatase activity towards Ins(1,3,4,5)P4;
FT                   dbSNP:rs1554825652)"
FT                   /evidence="ECO:0000269|PubMed:10866302,
FT                   ECO:0000269|PubMed:15355975"
FT                   /id="VAR_026276"
FT   VARIANT         342
FT                   /note="K -> N (in CWS1; reduced phosphatase activity
FT                   towards Ins(1,3,4,5)P4 but PtdIns(3,4,5)P3 phosphatase
FT                   activity is similar to wild-type; dbSNP:rs398123314)"
FT                   /evidence="ECO:0000269|PubMed:10866302"
FT                   /id="VAR_026277"
FT   VARIANT         343
FT                   /note="V -> E (in CWS1; loss of interaction with NOP53;
FT                   decreased phosphorylation at S-380; decreased stability;
FT                   loss of phosphatase activity towards Ins(1,3,4,5)P4)"
FT                   /evidence="ECO:0000269|PubMed:10866302,
FT                   ECO:0000269|PubMed:15355975, ECO:0000269|PubMed:9399897"
FT                   /id="VAR_008742"
FT   VARIANT         345
FT                   /note="L -> Q (in glioblastoma; reduced tumor suppressor
FT                   activity; loss of interaction with NOP53; decreased
FT                   phosphorylation at S-380; decreased stability; loss of
FT                   phosphatase activity towards Ins(1,3,4,5)P4; reduced
FT                   ability to inactivate AKT/PKB; retains ability to bind
FT                   phospholipid membranes)"
FT                   /evidence="ECO:0000269|PubMed:10468583,
FT                   ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:15355975,
FT                   ECO:0000269|PubMed:9331071"
FT                   /id="VAR_026278"
FT   VARIANT         347
FT                   /note="F -> L (in CWS1; reduced phosphatase activity
FT                   towards Ins(1,3,4,5)P4)"
FT                   /evidence="ECO:0000269|PubMed:10866302,
FT                   ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9399897"
FT                   /id="VAR_008743"
FT   VARIANT         348
FT                   /note="T -> I (in endometrial hyperplasia; reduced
FT                   phosphatase activity towards PtdIns(3,4,5)P3; mildly
FT                   reduced tumor suppressor activity; reduced ability to
FT                   inactivate AKT/PKB)"
FT                   /evidence="ECO:0000269|PubMed:10468583,
FT                   ECO:0000269|PubMed:9635567"
FT                   /id="VAR_026279"
FT   VARIANT         369
FT                   /note="V -> G (retains Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3
FT                   phosphatase activity; retains ability to bind phospholipid
FT                   membranes)"
FT                   /evidence="ECO:0000269|PubMed:10866302"
FT                   /id="VAR_026280"
FT   VARIANT         401
FT                   /note="T -> I (retains Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3
FT                   phosphatase activity; retains ability to bind phospholipid
FT                   membranes)"
FT                   /evidence="ECO:0000269|PubMed:10866302"
FT                   /id="VAR_026281"
FT   MUTAGEN         1
FT                   /note="M->I: Prevents expression of isoform 1 and increased
FT                   expression of isoform alpha."
FT                   /evidence="ECO:0000269|PubMed:24768297"
FT   MUTAGEN         13
FT                   /note="K->E: Nuclear. Cytoplasmic; when associated with
FT                   E-289. Shows less tumor suppressive ability; when
FT                   associated with E-289."
FT                   /evidence="ECO:0000269|PubMed:18716620"
FT   MUTAGEN         92
FT                   /note="D->A: 700-fold reduction in phosphatase activity
FT                   towards PtdIns(3,4,5)P3. Loss of protein phosphatase
FT                   activity. Unable to inhibit focal adhesion formation."
FT                   /evidence="ECO:0000269|PubMed:10555148,
FT                   ECO:0000269|PubMed:9616126"
FT   MUTAGEN         93
FT                   /note="H->A: 75% reduction in phosphatase activity towards
FT                   PtdIns(3,4,5)P3. Modest reduction in phosphatase activity
FT                   towards PtdIns(3,4)P2."
FT                   /evidence="ECO:0000269|PubMed:10555148"
FT   MUTAGEN         124
FT                   /note="C->A: Loss of protein phosphatase activity. Unable
FT                   to inhibit focal adhesion formation."
FT                   /evidence="ECO:0000269|PubMed:9616126"
FT   MUTAGEN         125
FT                   /note="K->M: Reduced phosphatase activity towards
FT                   PtdIns(3,4,5)P3, PtdIns(3,4)P2 and PtdIns(3)P."
FT                   /evidence="ECO:0000269|PubMed:10555148"
FT   MUTAGEN         126
FT                   /note="A->P: Does not reduce phosphatase activity towards
FT                   PtdIns(3,4,5)P3 and PtdIns(3,4)P2."
FT                   /evidence="ECO:0000269|PubMed:26504226"
FT   MUTAGEN         126
FT                   /note="A->S: Does not reduce phosphatase activity towards
FT                   PtdIns(3,4,5)P3 and PtdIns(3,4)P2."
FT                   /evidence="ECO:0000269|PubMed:26504226"
FT   MUTAGEN         126
FT                   /note="A->V: Does not reduce phosphatase activity towards
FT                   PtdIns(3,4,5)P3 and PtdIns(3,4)P2."
FT                   /evidence="ECO:0000269|PubMed:26504226"
FT   MUTAGEN         128
FT                   /note="K->M: 85% reduction in phosphatase activity towards
FT                   PtdIns(3,4,5)P3."
FT                   /evidence="ECO:0000269|PubMed:10555148"
FT   MUTAGEN         128
FT                   /note="K->R: Does not reduce phosphatase activity towards
FT                   PtdIns(3,4,5)P3."
FT                   /evidence="ECO:0000269|PubMed:10555148"
FT   MUTAGEN         130
FT                   /note="R->M: Does not affect the ability to inhibit AKT/PKB
FT                   activation."
FT                   /evidence="ECO:0000269|PubMed:9811831"
FT   MUTAGEN         167
FT                   /note="T->A,D: 60% reduction in phosphatase activity
FT                   towards PtdIns(3,4,5)P3."
FT                   /evidence="ECO:0000269|PubMed:10555148"
FT   MUTAGEN         171
FT                   /note="Q->A,E: 75% reduction in phosphatase activity
FT                   towards PtdIns(3,4,5)P3."
FT                   /evidence="ECO:0000269|PubMed:10555148"
FT   MUTAGEN         229
FT                   /note="S->A: No effect on interaction with DLC1 or p85."
FT                   /evidence="ECO:0000269|PubMed:26166433"
FT   MUTAGEN         232
FT                   /note="T->A: No effect on interaction with DLC1 or p85."
FT                   /evidence="ECO:0000269|PubMed:26166433"
FT   MUTAGEN         263..269
FT                   /note="KMLKKDK->AAGAADA: Reduces the growth suppression
FT                   activity and cells show anchorage-independent growth.
FT                   Reduces binding to phospholipid membranes in vitro.
FT                   Phosphatase activity towards PtdIns(3,4,5)P3 is not
FT                   affected."
FT                   /evidence="ECO:0000269|PubMed:10555148"
FT   MUTAGEN         289
FT                   /note="K->E: Cytoplasmic; when associated with E-13. Shows
FT                   less tumor suppressive ability; when associated with E-13."
FT                   /evidence="ECO:0000269|PubMed:18716620"
FT   MUTAGEN         319
FT                   /note="T->A: Reduces phosphorylation of the C2 tensin-like
FT                   domain and abolishes interaction with DLC1 following EGF
FT                   stimulation. Abolishes phosphorylation of the C2
FT                   tensin-like domain; when associated with A-321."
FT                   /evidence="ECO:0000269|PubMed:26166433"
FT   MUTAGEN         319
FT                   /note="T->E: Constitutive interaction with DLC1."
FT                   /evidence="ECO:0000269|PubMed:26166433"
FT   MUTAGEN         319
FT                   /note="T->Y: Constitutive interaction with DLC1 and
FT                   interaction with p85 following EGF stimulation."
FT                   /evidence="ECO:0000269|PubMed:26166433"
FT   MUTAGEN         321
FT                   /note="T->A: Reduces phosphorylation of the C2 tensin-like
FT                   domain and abolishes interaction with DLC1 following EGF
FT                   stimulation. Abolishes phosphorylation of the C2
FT                   tensin-like domain; when associated with A-319."
FT                   /evidence="ECO:0000269|PubMed:26166433"
FT   MUTAGEN         321
FT                   /note="T->E: Constitutive interaction with DLC1."
FT                   /evidence="ECO:0000269|PubMed:26166433"
FT   MUTAGEN         327..335
FT                   /note="KANKDKANR->AAGADAANA: Reduces growth suppression
FT                   activity and promotes anchorage-independent growth. Reduces
FT                   binding to phospholipid membranes in vitro; phosphatase
FT                   activity towards PtdIns(3,4,5)P3 is not affected."
FT                   /evidence="ECO:0000269|PubMed:10555148"
FT   MUTAGEN         336
FT                   /note="Y->F: Significantly lower phosphatase activity,
FT                   reduced protein stability and decreased growth-inhibitory
FT                   effect."
FT                   /evidence="ECO:0000269|PubMed:19345329"
FT   MUTAGEN         366
FT                   /note="T->A: Decreased stability."
FT                   /evidence="ECO:0000269|PubMed:20940307"
FT   MUTAGEN         370
FT                   /note="S->A: Decreased stability."
FT                   /evidence="ECO:0000269|PubMed:20940307"
FT   MUTAGEN         401
FT                   /note="T->A: Loss of DLG1-binding. No effect on MAGI2- and
FT                   MAST2-binding."
FT   MUTAGEN         402
FT                   /note="K->A: No effect on MAGI2-, MAST2- and DLG1-binding."
FT   MUTAGEN         402
FT                   /note="K->W: Loss of DLG1-, MAGI2-, MAGI3- and
FT                   MAST2-binding. Decrease of protein stability."
FT   MUTAGEN         403
FT                   /note="V->A: Loss of DLG1-, MAGI2-, MAGI3-, MAST1-,
FT                   MAST2- and MAST3-binding."
FT                   /evidence="ECO:0000269|PubMed:15951562"
FT   HELIX           8..10
FT                   /evidence="ECO:0007829|PDB:7JUL"
FT   TURN            19..22
FT                   /evidence="ECO:0007829|PDB:1D5R"
FT   STRAND          23..29
FT                   /evidence="ECO:0007829|PDB:1D5R"
FT   STRAND          32..35
FT                   /evidence="ECO:0007829|PDB:1D5R"
FT   STRAND          39..41
FT                   /evidence="ECO:0007829|PDB:1D5R"
FT   STRAND          44..47
FT                   /evidence="ECO:0007829|PDB:5BZZ"
FT   HELIX           50..60
FT                   /evidence="ECO:0007829|PDB:1D5R"
FT   STRAND          61..63
FT                   /evidence="ECO:0007829|PDB:1D5R"
FT   STRAND          65..73
FT                   /evidence="ECO:0007829|PDB:1D5R"
FT   HELIX           78..80
FT                   /evidence="ECO:0007829|PDB:5BZZ"
FT   STRAND          81..83
FT                   /evidence="ECO:0007829|PDB:5BZZ"
FT   STRAND          85..90
FT                   /evidence="ECO:0007829|PDB:1D5R"
FT   HELIX           98..100
FT                   /evidence="ECO:0007829|PDB:1D5R"
FT   HELIX           101..112
FT                   /evidence="ECO:0007829|PDB:1D5R"
FT   TURN            113..115
FT                   /evidence="ECO:0007829|PDB:1D5R"
FT   STRAND          118..123
FT                   /evidence="ECO:0007829|PDB:1D5R"
FT   STRAND          125..128
FT                   /evidence="ECO:0007829|PDB:1D5R"
FT   HELIX           129..141
FT                   /evidence="ECO:0007829|PDB:1D5R"
FT   HELIX           148..159
FT                   /evidence="ECO:0007829|PDB:1D5R"
FT   STRAND          161..163
FT                   /evidence="ECO:0007829|PDB:1D5R"
FT   HELIX           169..184
FT                   /evidence="ECO:0007829|PDB:1D5R"
FT   STRAND          192..202
FT                   /evidence="ECO:0007829|PDB:1D5R"
FT   STRAND          206..209
FT                   /evidence="ECO:0007829|PDB:5BZZ"
FT   STRAND          213..219
FT                   /evidence="ECO:0007829|PDB:1D5R"
FT   STRAND          222..226
FT                   /evidence="ECO:0007829|PDB:1D5R"
FT   STRAND          232..235
FT                   /evidence="ECO:0007829|PDB:1D5R"
FT   STRAND          238..259
FT                   /evidence="ECO:0007829|PDB:1D5R"
FT   STRAND          262..264
FT                   /evidence="ECO:0007829|PDB:5BZZ"
FT   STRAND          268..276
FT                   /evidence="ECO:0007829|PDB:1D5R"
FT   HELIX           277..279
FT                   /evidence="ECO:0007829|PDB:1D5R"
FT   STRAND          280..284
FT                   /evidence="ECO:0007829|PDB:5BZZ"
FT   STRAND          310..312
FT                   /evidence="ECO:0007829|PDB:5BZX"
FT   STRAND          315..321
FT                   /evidence="ECO:0007829|PDB:1D5R"
FT   HELIX           322..324
FT                   /evidence="ECO:0007829|PDB:1D5R"
FT   HELIX           328..330
FT                   /evidence="ECO:0007829|PDB:1D5R"
FT   STRAND          335..337
FT                   /evidence="ECO:0007829|PDB:1D5R"
FT   STRAND          342..349
FT                   /evidence="ECO:0007829|PDB:1D5R"
FT   STRAND          395..403
FT                   /evidence="ECO:0007829|PDB:2KYL"
SQ   SEQUENCE   403 AA;  47166 MW;  75F97C3DD6802BA9 CRC64;
     MTAIIKEIVS RNKRRYQEDG FDLDLTYIYP NIIAMGFPAE RLEGVYRNNI DDVVRFLDSK
     HKNHYKIYNL CAERHYDTAK FNCRVAQYPF EDHNPPQLEL IKPFCEDLDQ WLSEDDNHVA
     AIHCKAGKGR TGVMICAYLL HRGKFLKAQE ALDFYGEVRT RDKKGVTIPS QRRYVYYYSY
     LLKNHLDYRP VALLFHKMMF ETIPMFSGGT CNPQFVVCQL KVKIYSSNSG PTRREDKFMY
     FEFPQPLPVC GDIKVEFFHK QNKMLKKDKM FHFWVNTFFI PGPEETSEKV ENGSLCDQEI
     DSICSIERAD NDKEYLVLTL TKNDLDKANK DKANRYFSPN FKVKLYFTKT VEEPSNPEAS
     SSTSVTPDVS DNEPDHYRYS DTTDSDPENE PFDEDQHTQI TKV
//
